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Certainty in science went out of fashion early last century following Heisenberg’s postulates.  
We now see ranges and confidence intervals around any given mode, mean, or median.  
Truth, in short, is a dependent variable. 
 
R. David G. Leslie & Eric S. Kilpatrick 
Diabetes Care, 2009 Jan;32(1):e11 
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Preface 
 
Since the earliest steps in this Doctoral Program I envisioned this journey as 
consisting of three steps: (1) to become comfortable with the state-of-the-art of 
genetic epidemiology and get organizational skills to correctly and productively 
frame ideas, manage datasets and biobanks and to deal with international research 
consortia; (2) to learn how to compellingly write research proposals and scientific 
reports, discuss and share results, critically review and support the work of other 
research groups involved in the field of diabetes, obesity and cardiovascular 
disease from a wide variety of perspectives (from wet lab to clinical 
epidemiology); (3) to finalize for publication original research papers on the 
topics outlined above. 
 
To this end, in 2013-2014 I had the opportunity to get a formal training in 
scientific methodology and writing, epidemiology, medical and population 
genetics at Harvard University in Boston. This experience led to the publication 
of several papers in high-impact scientific journals and continuing collaboration 
with the Framingham Heart Study group, MAGIC and CHARGE Consortia is still 
fruitfully ongoing. Since my arrival back in Italy in July 2014 I have continued to 
work on the projects I started in Boston, while disseminating scientific knowledge 
by actively attending to several national and international meetings.  
 
The unprecedented experience accrued while working with the Framingham 
Investigators and other international leaders in the field of (genetic) epidemiology 
led to create the overarching framework of my current activity, which aims at 
bringing together the genetic determinants of diabetes, obesity, cardiovascular 
disease and intermediate traits and to understand their relationship with the 
pathophysiology of the glucose-insulin system. 
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T2D is a complex disease characterized by a high prevalence and incidence 
worldwide, and recognizes genetic and non-genetic (environmental) risk factors 
as underlying determinants. CVD are currently one of the leading causes of death 
and are also often clinically associated to T2D. Recent large-scale genome-wide 
association studies (GWAS) have identified common genetic risk variants 
associated with a higher propensity of developing T2D, CVD and intermediate 
cardiometabolic phenotypes.  
 
The goal of the research project herein presented was three-fold: (1) to critically 
revise the available literature about the genetic determinants of type 2 diabetes 
(T2D), coronary heart disease (CHD) and intermediate phenotypes (sub-diabetic 
hyperglycemia, measures of subclinical atherosclerosis (SCA) and associated risk 
conditions), aimed at searching for potential overlapping areas of shared genetic 
background; (2) to verify whether the genetic determinants of T2D, and 
particularly those associated with insulin resistance, are also associated with 
measures of SCA; (3) to verify whether a genetic risk score comprised of the 
genetic determinants of T2D, myocardial infarction, stroke, atrial fibrillation, 
sudden cardiac death, coronary heart disease, is associated with an excess risk of 
all-cause mortality and/or CVD death.  
 
In detail, the present research exercise aimed at exploring the common genetic 
background of T2D, CVD and sub-diabetic forms of hyperglycemia by means of 
three exemplifying studies herein outlined. The first study verified whether the 
genetic risk for T2D, as represented by the aggregate burden of T2D risk loci 
(either as a whole or by distinct functional sub-groups, representative of loci with 
prior evidence of association with defective beta-cell function and/or increased 
insulin resistance), is associated with SCA traits in multi-ethnic cohorts.  
The second study verified the hypothesis that the common genetic variability at 
loci gatekeepers of the insulin signaling transduction pathway are associated with 
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insulin resistance, beta-cell dysfunction, pathologic electrocardiogram, and/or 
increased SCA in patients affect by newly-diagnosed T2D. 
The third study verified whether the composite of the genetic determinants of 
T2D and intermediate CVD risk traits is associated with a higher mortality in the 
Framingham Offspring Study. 
 
 
 
Prefazione 
 
Il presente progetto di ricerca si compone di tre parti: (1) revisione della 
letteratura relativa ai determinanti genetici di diabete mellito tipo 2, malattie 
coronariche e fenotipi intermedi (forme sub-diabetiche di iperglicemia, forme 
subcliniche di aterosclerosi e fattori di rischio associati) alla ricerca di possibili 
aree di sovrapposizione; (2) verificare se i determinanti di rischio genetico per 
diabete tipo 2, ed in particolare quelli maggiormente associati a insulino-
resistenza, sono anche associati a misure di aterosclerosi subclinica; (3) verificare 
se uno score di rischio genetico costituito dai determinanti genetici di diabete tipo 
2, infarto miocardico, stroke, fibrillazione atriale, morte cardiaca improvvisa, 
malattie coronariche è associato a mortalità per tutte le cause e/o mortalità per 
malattie cardiovascolari.  
 
Il diabete mellito di tipo 2 (T2D) è una malattia complessa ad alta prevalenza e 
incidenza che riconosce fattori genetici e non-genetici quali determinanti causali. 
Le malattie cardiovascolari (CVD) sono una delle maggiori cause di morte e sono 
spesso associate a T2D. Studi di associazione genome-wide hanno identificato 
varianti genetiche comuni associate a T2D, CVD e fenotipi cardiometabolici 
intermedi.  
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Questo percorso di ricerca si è proposto di individuare le basi genetiche comuni a 
T2D, CVD e forme sub-diabetiche di iperglicemia attraverso tre studi 
esemplificativi. Nel primo studio è stato verificato se il rischio genetico per T2D 
sia associato, in aggregato e/o in sottogruppi funzionali distinti (disfunzione beta-
cellulare o insulino-resistenza), a tratti di aterosclerosi subclinica (ATS) in coorti 
multi-etniche. Il secondo studio ha testato l’ipotesi che la variabilità genetica 
comune dei loci principalmente coinvolti nella trasduzione del segnale insulinico 
siano associati a insulino-resistenza, funzione beta-cellulare, anomalie 
elettrocardiografiche e/o aterosclerosi subclinica in soggetti affetti da T2D neo-
diagnosticato. Nel terzo studio è stato indagato se il rischio genetico per T2D e 
tratti di rischio cardiometabolico sia associato ad aumentata mortalità nel 
Framingham Offspring Study. 
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Chapter 2 
 
 
Current Insights into the Joint Genetic Basis of 
Type 2 Diabetes and Coronary Heart Disease 
Curr Cardiovasc Risk Rep (2014) 8(1):368 
Authors and affiliations are listed in Chapter 6.1 
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2.1 ABSTRACT 
 
English - The large-scale genome-wide association studies conducted so far 
identified numerous allelic variants associated with type 2 diabetes (T2D), 
coronary heart disease (CHD) and related cardiometabolic traits. Many T2D- and 
some CHD-risk loci are also linked with metabolic traits that are hallmarks of 
insulin resistance (lipid profile, abdominal adiposity). 9p21.3 and 2q36.3, are the 
most consistently replicated loci appearing to share genetic risk for both T2D and 
CHD. Although many glucose- or insulin-related trait variants are also linked with 
T2D risk, none of them is associated with CHD. Hence, while T2D and CHD are 
strongly clinically linked together, further ongoing analyses are needed to clarify 
the existence of a shared underlying genetic signature of these complex traits. The 
present review summarizes an updated picture of T2D-CHD genetics as of 2013, 
aiming to provide a platform for targeted studies dissecting the contribution of 
genetics to the phenotypic heterogeneity of T2D and CHD.  
 
Italian - Gli studi su larga scala del genoma hanno sinora identificato numerose 
varianti alleliche associate a diabete mellito tipo 2 (DMT2), malattie coronariche 
(CHD) e a fenotipi intermedi di rischio cardiometabolico. Molti loci associati a 
DMT2 ed alcuni associati a CHD sono anche associati a tratti metabolici 
caratteristici dell’insulino-resistenza (profilo lipidico, adiposità addominale). I 
loci 9p21.3 e 2q36.3 sono stati più volte identificati quali determinanti genetici di 
rischio all’intersezione tra DMT2 e CHD. Benchè tuttavia molte varianti 
genetiche associate a glicemia, insulinemia e fenotipi ad essi correlati siano anche 
associate a un aumentato rischio per DMT2, nessuna è risultata associata a CHD. 
Pertanto, benchè sia evidente che DMT2 e CHD sono fortemente associati 
clinicamente, ulteriori studi sono necessari per chiarire se questi complessi 
fenotipi riconoscano una base genetica comune. In questo riassunto viene fornito 
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un quadro aggiornato delle conoscenze relativa ai determinanti genetici di DMT2 
e CHD e si propone di fornire una base per esplorare l’eterogeneità fenotipica che 
caratterizza DMT2 e CHD. 
 
 
 
 
Abbreviations 
 
CARDIoGRAM Coronary ARtery DIsease Genome wide Replication and 
Meta-analysis Consortium 
C4D   Coronary Artery Disease Genetics Consortium 
DIAGRAMv3  DIAbetes Genetics Replication and Meta-analysis 
MAGIC Meta-Analyses of Glucose- and Insulin-related traits 
Consortium 
WTCC   Wellcome Trust Case Control Consortium 
GWAS  Genome Wide Association Study 
T2D   Type 2 Diabetes  
CHD   Coronary Heart Disease 
MI   Myocardial Infarction 
LD    Linkage Disequilibrium 
SNP   Single Nucleotide Polymorphism  
MAF   Minor Allele Frequency 
BMI   Body Mass Index 
WHR   Waist-to-Hip Ratio 
HOMA-B  Homeostatic Model Assessment of Beta-Cell Function 
HOMA-IR  Homeostatic Model Assessment of Insulin Resistance 
HUVEC  HUman Vascular Endothelial Cells 
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2.2  INTRODUCTION 
 
The global epidemic of type 2 diabetes (T2D) and associated cardiovascular 
diseases is increasing tremendously despite great efforts in prevention and 
treatment [1]. Cardiovascular diseases, especially coronary heart disease (CHD), 
represent the leading cause of death worldwide [2] and alarming projections for 
upcoming years require new and more effective strategies [3]. 
Better understanding of mechanisms underlying disease etiology and disease 
pathogenesis is the sine qua non to move forward and is a major goal of recent 
genetic studies on T2D and CHD [4]. Both T2D and CHD constitute the paradigm 
of common complex traits and have been an exciting and highly productive arena 
in the field of genetics: the last decade witnessed an impressive growth of 
available information about the genetic architecture of T2D and CHD. 
Interestingly, the growing amount of available information has revealed many 
apparently overlapping genetic signals that share association with T2D and CHD, 
especially in and near chromosome 9p21.3 [5-9] and 2q36.3 [10, 11], and at 
several other loci harboring variants associated with fasting glucose or insulin and 
other cardiometabolic traits (for instance, levels of lipids and anthropometric 
measures) that increase risk for CHD and/or T2D [12, 13].  
The present review will outline and discuss the results from large-scale 
association analyses for T2D [14], CHD [15] and glycaemic traits [12] published 
in the last year (2012-2103), and integrate the evidence on chromosomal regions 
at 9p21.3 and 2q36.3 loci to provide a plausible, though not exhaustive, 
explanation at the genetic level of the common soil underlying CHD, T2D and 
associated metabolic traits. 
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2.2.1 Recent Type 2 Diabetes Genome-Wide Association Studies (GWAS) 
 
In 2012, the DIAbetes Genetics Replication and Meta-analysis Consortium 
published the largest to date association analysis for T2D (DIAGRAMv3) [14]. 
The study, combined with the 2011 genome-wide association study (GWAS, see 
the glossary in Table 1) of Cho et al. [16] in roughly 55,000 East Asians, brought 
to 65 the number of independent T2D susceptibility loci (Table 2), thus further 
extending an effort begun a few years ago [17] to unveil the common allelic 
architecture of T2D. The strategy took advantage of the experience accumulated 
in the field of GWAS and the availability of the Metabochip custom array [18] for 
cost-effective follow-up genotyping. The case-control, two-stage DIAGRAMv3 
meta-analysis was conducted in nearly 150,000 subjects (34,840 T2D cases and 
114,981 controls) mostly of European ancestry from 38 independent cohorts. The 
study found 10 new T2D variants of modest effect size in or near ZMIZ1, ANK1, 
KLHDC5, TLE1, ANKRD55, CILP2, MC4R, BCAR1, HMG20A and GRB14. 
Linkage disequilibrium (LD) analysis and previous reports showed that the lead 
SNP at many of these loci was also associated with T2D-related metabolic traits 
that overlap CHD risk factors such as body-mass index (BMI), waist 
circumference, and insulin resistance (MC4R), triglyceride concentration (MC4R, 
CILP2), waist-to-hip ratio (WHR) (GRB14), HDL-cholesterol (GRB14, CILP2) 
and total-cholesterol (CILP2). Interestingly, as clearly shown in Figure 1 and 
thoroughly detailed in the following sections, there is also compelling evidence 
that specific T2D loci on chromosome 2q36.3 and 9p21.3 harbor allelic variants 
in close proximity to each other and marking genomic regions associated with 
increased CHD risk.  
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2.2.2  Recent Coronary Heart Disease GWAS 
 
As detailed in Table 2 the number of loci currently known to be associated with 
coronary heart disease at genome-wide significance level have reached 45, thanks 
to the joint effort undertaken by the CARDIoGRAM-C4D Consortium on a 
sample of nearly 200,000 individuals (63,746 CHD cases and 130,681 controls in 
Stage1 + Stage2) [15]. This study, published in early 2013, confirmed previous 
findings [11, 19], discovered 15 new genome-wide significant loci and tested 
them by a thorough association analysis with traditional CHD risk factors. Twelve 
loci (APOB, ABCG5-ABCG8, PCSK9, SORT1, ABO, LDLR, APOE and LPA) 
showed genome-wide significance for association with at least one lipid trait in 
the expected direction. The CHD-raising allele was also associated with abnormal 
lipid levels, the strongest association being with LDL-cholesterol; CYP17A1-
NT5C2, SH2B3, GUCY1A3, FES and ZC3HC1 were associated with blood 
pressure; CYP17A1-CNNM2-NT5C2 and RAI1-PEMT-RASD1 loci were 
associated with BMI and WHR. Notably, there was no overlap with specific T2D 
or glycaemic trait-associated variants (fasting insulin, fasting plasma glucose, 
HOMA-B and HOMA-IR) for any of the SNPs analyzed (Figure 1).  
 
Taken together, the overall spectrum of 65 T2D and 45 CHD genome-wide 
associated common variants explain only a small fraction (∼10% each) of disease 
heritability, thus leaving a large unfilled space under the umbrella of the common 
variant/common disease hypothesis [20]. Indeed, a great proportion of common 
genetic variance is predicted to occur in non-coding regions at the level of 
structural variation, such as deletions, insertions, inversions and copy number 
variants, which might be imperfectly tagged or under-represented in current 
GWAS arrays [21].  Large scale sequencing studies currently underway may help 
to fill in some of the unfilled space under the umbrella of the genetic basis of T2D 
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and CHD by identifying less common or regulatory variants underlying these 
diseases.  
 
 
2.2.3  Recent Glycaemic Quantitative Traits GWAS 
 
Valuable details concerning quantitative risk factors were added to the overall 
picture in 2012 by two large-scale association analyses from the Meta-Analyses 
of Glucose and Insulin-related traits (MAGIC) Consortium [12, 22] that further 
enlightened our understanding of the genetic determinants of overlapping risk 
factors for T2D and CHD (see Table 3). 
The joint meta-analysis by Manning et al. [22] in nearly 100,000 non-diabetic 
subjects of European ancestry investigated the genetic variability of insulin 
resistance by testing on a genome-wide basis the interaction of body mass index 
with fasting glucose and insulin. Based on previous experience from MAGIC [23] 
a new computational approach accounting for potential interactions between BMI 
and genetic variants was applied, enabling the discovery of 13 previously 
unknown SNPs associated with fasting insulin (FI) or fasting glucose (FG) at 
genome-wide significance. Among the FI-loci, the lead SNP in or near IRS1, 
COBLL1-GRB14, PDGFC or LYPLA1 was also associated with an increased risk 
for T2D (Figure 1, Table 3), the strongest signal being for the chr2q36.3-IRS1 
locus (rs2943634). Notably, as detailed in Table 3, the risk allele of most of the 
FI-SNPs identified were also associated with metabolic phenotypes related to 
insulin resistance and CHD risk (for instance, detrimental lipid profile, higher 
WHR). None of the FG-loci showed association with any insulin resistance-
cardiometabolic trait, and only ARAP1 was associated with T2D (Table 3).   
These results are complementary to the GWAS conducted by Scott et al. [12], 
which identified 41 previously undiscovered [23, 24] glycaemic associations in up 
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to 133,010 non-diabetic individuals of European descent by combining previous 
discovery MAGIC data with newly Metabochip-genotyped samples. Scott et al. 
and Manning et al. jointly raised the number of non-overlapping loci influencing 
glycaemic traits (FI, FG, post-challenge glucose concentration) to 55 (53 
confirmed loci in Scott et al. plus 2 additional and potentially independent signals 
from Manning et al., associated with FG and lying, respectively, in or near OR4S1 
and DPSYL5 genes); 34 of them are also at least nominally associated with 
increased T2D risk (Figure 1), and most of the FI-raising loci showed 
directionally consistent associations with abdominal obesity and/or higher 
triglycerides-to-HDL cholesterol ratio (Tg/HDL) (Table 3). 
 
 
2.3 THE CHROMOSOME 2q36.3-IRS1 LOCUS 
 
The evidence described above suggests that loci associated with signatures of 
insulin resistance are fairly good candidates mechanistically linking the overlap 
between T2D, CHD and glycaemic quantitative traits. As pointed out in Figure 1 
and Figure 2, one of the most promising regions is a large locus spanning ∼593 
kb located on chromosome 2q36.3 and harboring the IRS1 gene, a key mediator 
along the insulin signaling pathway. Over the past few years many large-scale 
association studies from different research groups including Manning et al. and 
Scott et al. led to the identification of a cluster of SNPs (rs2943634, rs2043640, 
rs2943641, rs2943650, rs2972146, rs2943645) in high LD with each other 
(0.75<r2<1.00; 1000 Genomes Pilot 1 CEU population) and associated with T2D, 
CHD, increased FI, higher Tg/HDL and/or low subcutaneous-to-visceral fat ratio 
[11-14, 22, 25, 26]. A recent basic science report by Li et al. [27] also clarified 
that these variants are located in two major sites ∼600 kb and ∼1 Mb downstream 
from the IRS1 gene promoter and might physically regulate IRS1 gene expression 
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by looping interactions, explaining how putative regulatory regions far from IRS1 
might regulate insulin sensitivity. The variant rs2943634 deserves a special 
mention (Figure 2A) as the only one SNP discovered so far in 2q36.3 region 
directly associated with increased CHD risk –though at slightly below genome-
wide significant (p=1.61x10-7) by the WTCC and Cardiogenics Consortium 
GWAS effort in 2007 [11]. 
That said, since insulin resistance and its associated traits have also been proposed 
as common pathophysiological background underlying CHD risk and the diabetic 
atherogenic context [28], Lim et al. [29] early in 2013 further investigated 
whether the genetic variation at 2q36.3 locus might also affect CHD risk via 
subclinical atherosclerosis in a sample of 2740 Framingham Heart Study 
participants. The study examined the cluster of SNPs described above along with 
195 additional genotyped or imputed SNPs in 2q36.3 locus, testing them for 
association with subclinical atherosclerosis traits, but failed to find any 
correlation, despite an adequate sample size and detailed phenotypic 
characterization. The only significant association between rs10167219 (r2 with 
rs2943634 = 0.07) and ankle-brachial index (ABI) was not confirmed after a 
validation step in a larger ABI meta-analysis [30].  
On the other hand, Bacci et al. [10] found that functional candidate variants of 
insulin signaling genes, including IRS1 G972R (rs1801278) (regional plot shown 
in Figure 2B), ENPP1 K121Q (rs1044498) and TRIB3 Q84R (rs229549), 
summed in a genetic risk score (GRS), jointly nominally predicted a composite 
endpoint of incident cardiovascular events in a sample of 733 type 2 diabetic 
patients, The GRS was also associated with decreased insulin sensitivity, and 
functional analysis in human vascular endothelial cells (HUVEC) showed that the 
GRS was inversely related with insulin-stimulated nitric oxide synthase activity.   
Hence, depending on the outcome measured, whether atherosclerotic plaque 
formation or coronary heart disease events, current insights on 2q36.3 locus are 
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still far from conclusive with much remaining to be understood at a mechanistic 
level.  
 
 
2.4 THE CHROMOSOME 9p21.3 LOCUS 
 
As shown in Figure 1 and Table 2, only two of the 65 T2D genome-wide 
associated loci [14, 16] but none of the common variants at these loci clearly 
overlaps any of the 45 CHD loci [15]. The example provided by 9p21.3 locus, a 
large genomic region spanning ∼53 kb, is paradigmatic in this sense, owing to its 
unique haplotype structure (Figure 2B). Notably, this locus is associated with 
both CHD and T2D in European ancestry individuals [5, 7-9] and also in Chinese 
Han individuals as shown in 2011 by Cheng et al. [6].  
The 9p21.3 locus has been extensively studied over the past years and has been 
historically primarily linked with an increased risk of CHD and myocardial 
infarction [11, 31], as confirmed by the recent GWAS conducted by 
CARDIoGRAM-C4D Consortium [15]. The numerous CHD-associated SNPs 
identified thus far in this interval are characterized by high LD with each other, 
thus representing a distinct region robustly associated with CHD. In 2013 
additional insights in the haplotype structure of this CHD-risk interval have 
become available. In a case-control study conducted in nearly 3,700 non-diabetic 
white subjects, Fan et al. [32] successfully showed that atherosclerotic plaque 
formation is determined by a set of allelic variants physically distinct from the 
haplotype that predicts MI, namely, vulnerable plaque rupture and thrombosis. 
The 9p21.3 locus does not house protein-coding genes; the closest, CDKN2ABS1, 
CDKN2A/B, and ABO, are 120 kb from the principal index SNPs at the locus. As 
well highlighted by a recent editorial by McPherson [33], a mechanistic 
explanation to unambiguously clarify the contribution of 9p21.3 CHD-associated 
 					
31 
SNPs to atherosclerosis and MI is still missing. Long range regulatory interactions 
with distant coding regions, tissue-specific effects of 9p21.3 CHD susceptibility 
SNPs and interactions with inflammation have been hypothesized, [34], but 
current results are conflicting and a clear mechanistic model for the genetic 
effects at this locus remain to be identified [35, 36].  
With respect to T2D risk, as found by Morris et al. [14], chromosome 9p21.3 also 
encompasses variants strongly associated with T2D (Table 2) and spatially 
arranged in a very tight genomic region adjacent but distinct from that harboring 
the CHD-associated SNPs. As shown in Figure 2C-D, it is well ascertained that 
the haplotype structure of 9p21.3 locus stands on two main regions or “blocks” 
[8]: one large segment spans roughly 44 kb and hosts the CHD LD region (lead-
SNP: rs1333049); on the other side of a recombination peak lies a 4kb T2D-
associated block (lead-SNP: rs10811661). The LD between the respective lead-
SNPs of T2D and CHD blocks [15] is very low (r2<0.009; 1000 Genomes Pilot 1 
CEU population). The two regions have a low chance of mixing together during 
recombination, thus suggesting a distinct pattern of inheritance.  
However, the DIAGRAMv3 GWAS identified an additional lead SNP at a 
putative independent secondary T2D signal (rs944801; r2=0.01 with rs10811661) 
[14] within the CHD-haplotype block (Figure 3C). This T2D-associated SNP is 
in modest LD (r2=0.35) with the CHD lead-SNP (rs1333049), thus indicating a 
potential region close to the CDKN2A/B genes jointly affecting CHD and T2D.  
Functional studies to parse in depth the contribution, if any, to both T2D and 
CHD of this and other variants within 9p21.3 locus is a challenging task that is 
worth pursuing further. 
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2.5  SUMMARY 
  
Large-scale GWAS have been a powerful tool to uncover common genetic 
signatures strongly associated with common complex diseases like T2D, CHD 
and associated cardiometabolic traits. Here we reviewed the most recent findings 
in this field, highlighting the hitherto confirmed overlapping associations among 
T2D, CHD and glycaemic trait susceptibility loci.  
The papers in the last year by the DIAGRAM, Cardiogram-C4D and MAGIC 
consortia showed that a few GWAS-discovered loci overlap both T2D and CHD 
risk, and for quantitative traits, a larger fraction of glycaemic trait raising alleles 
are also associated with T2D risk and CHD quantitative risk factors. In particular, 
FI-raising alleles show a directionally consistent link with increased T2D risk and 
adverse lipid and anthropometric measures. These results suggest that many FI-
associated loci represent insulin resistance loci that potential provide a genetic 
underpinning for joint T2D-CHD risk. The 2q36.3-IRS1 locus in particular has 
emerged as a crossroad for signals associated with T2D-CHD risk. However, a 
firm and comprehensive functional explanation of the role played by 2q36.3-IRS1 
remains to be shown, especially towards CHD risk. For instance, 2q36.3 locus 
harbors variants that, taken together, seem to play heterogeneous genetic effects 
on atherosclerotic plaque formation/rupture [10, 29]. Interestingly, compelling 
evidence exists for the association between cardiovascular events and the 
candidate functional variant IRS1 G972R (rs1801278) [10]. Unfortunately, this 
variant lacks of GWAS confirmation despite being quite common (MAF 5.4%), 
probably because no proxy for rs1801278 mapping in or near other known 
variants in 2q36.3 locus is presently available in any available SNP data set. Thus, 
absence of evidence for a clear role of this variant is due to absence of evidence, 
not evidence of no role. Genotyping of this variant in large, independent samples 
is needed for firm confirmation of this coding variant’s role in CHD risk.  
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The role of the 9p21.3 locus on T2D-CHD risk needs further elucidation, as well. 
It has a peculiar haplotype structure organized in two contiguous but distinct 
blocks conferring risk, respectively, for T2D and CHD/MI. However there 
appears to be a variant, rs944801, that may be an independent secondary T2D 
signal amidst the CHD-haplotype block. Targeted confirmatory association and 
functional studies are needed to further investigate joint risk of T2D-CHD in this 
haplotype block.  
 
 
2.6  IMPLICATIONS AND FUTURE DIRECTIONS 
 
A number of possible confounding elements may explain why association results 
should be taken with, perhaps, a grain of salt [21, 37, 38]. First, as pointed out by 
Wray et al.  [38], GWAS are capable, by design, to explain only a small fraction 
(currently 10%, on average) of disease heritability and are intrinsically 
underpowered to uncover the “missing inheritance” carried by rare and low-
frequency variants; second, the nature of the association is essentially statistical 
and in most cases doesn't tell much about the functional effect, if any, of the SNPs 
identified, thus limiting the predictive power of the loci discovered so far [21]; 
third, most of the GWAS SNPs lie in non-coding DNA regions and might work as 
regulatory or chromatin-modulating variants with unknown distant cis/trans effect 
on gene expression [37]; and finally, possible limitations including imperfect 
tagging due to insufficiently dense SNP arrays cannot be excluded.  
 
Another possibility is that diabetic and non-diabetic individuals might have 
distinct mechanisms of CHD risk. For instance, an increased burden of T2D-
associated GWAS risk variants is associated with cardiovascular disease risk in 
individuals with T2D [39], but CHD risk at chromosome 9p21.3 is only raised in 
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T2D among those with elevated HbA1c levels [40], and the recently discovered 
variant on chromosome 1q25 associated with glutamic acid metabolism and CHD 
risk in T2D has not been observed in large scale non-diabetic CHD GWAS [41]. 
Further dissection of the joint genetic association of T2D and CHD versus the 
interaction of T2D on genetic risk for CHD will require additional careful 
untangling in large scale association studies and follow-up functional and 
physiological studies.  
 
Future research might also focus on pleiotropy analyses of variants with less 
stringent evidence for genome-wide significance. For instance, as detailed in 
Table 3, the link between glycaemic trait raising alleles with lipids and BMI is 
physiologically consistent and statistically convincing for “true” associations, 
though in most cases not strong enough to reach p<5x108. Whether these loci that 
appear to be associated with more than one trait are true pleiotropic loci or more a 
function of the known trait correlations (that is, greater adiposity is a well-known 
correlate of insulin resistance) remains to be elucidated. In addition, studies that 
leverage extended genealogy [42] to catch more of the “missing heritability” and 
improve polygenic risk prediction [43] combined with targeted re-sequencing and 
fine-mapping studies of confirmed loci like 2q36.3 and 9p21.3 may also help to 
untangle the joint association of T2D-CHD [44].  
Furthermore, increasing the prior probability to find “true” associations would be 
of paramount help. To this end it might be wise to focus on studies of carefully 
selected, deeply phenotyped population samples with a priori stronger genetic 
background like early-onset diabetes [45] or cohorts free of confounding factors 
like long standing (sub)diabetic hyperglycaemia [46]. The availability of detailed 
assessments of beta-cell function and insulin sensitivity (instead of surrogate 
markers) as well as the accessibility of tissue- and cell-repositories within these 
population samples will also provide the unique opportunity to mechanistically 
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unravel the genetic signature of T2D and/or CHD. 
 
Greater understanding of the genetic associations underlying T2D-CHD risk in 
the setting of a global pandemic of T2D and CHD is a timely challenge for 
improved population health and the sustainability of healthcare systems. The 
tremendous abundance of discoveries made by large-scale association studies 
published in 2012-2013 now needs further translation into mechanistic insights 
and improved clinical practice. However, this promise for discoveries achieved in 
the field of diabetes and cardiometabolic disease genetics is becoming ever closer.  
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2.7 FIGURES and TABLES 
 
 
Table 1 - Glossary of Unfamiliar Terms 
 
 
SNP: A Single Nucleotide Polymorphism (SNP) is a single base-pair change in the DNA 
sequence and is a class of common human genetic variations [47]. A genetic variant is 
usually considered as “common” if its Minor Allele Frequency (MAF) is over 5%, i.e. the 
less frequently inherited allele on one of the two DNA strands has a prevalence over 5% 
in the population of interest.  
 
 
Linkage Disequilibrium: The difference between the expected and the observed 
frequencies of two SNPs under the assumption of independence is a common way to 
determine and measure the structure of haplotypes in genetic linkage analysis. This 
probability is called linkage disequilibrium (LD) and is expressed as a correlation 
coefficient ( r2 ) between pairs of SNPs, with r2 ranging between 0 and 1) The higher the 
r2, the higher the probability that two SNPs are non-randomly inherited together during 
recombination.  
 
 
GWAS: Genome-Wide Association Study. GWAS have become global scientific efforts 
begun over 10 years ago to analyze DNA sequence variations and to identify their 
possible association with common diseases by a hypothesis-free approach. For a general 
overview of basic principles, experimental design and overall computational strategy 
underlying GWAS we recommend the recent publication of Bush et al. [48]. 
 
 
Lead SNP: is the representative variant in a genomic region (or “locus”) most 
significantly associated with the disease or trait in a GWAS. As a general agreement, the 
lead SNP “tags” (or is a “tag-SNP”) an LD region and is named as being associated with 
the nearest known gene at the locus, if any. Further mapping and function studies are also 
required to determine if the lead SNP at a locus is actually associated with the named 
gene or has any molecular functional significance related to the disease or trait being 
studied. 
 
Statistical significance in GWAS: Since currently available GWAS genotyping 
platforms allow to test millions of SNPs together against one or more traits of interest 
across thousands of individuals, the agreement of what has to be considered statistically 
significant (i.e. accepted as true association rather than happened by chance) takes into 
account the nominal Pearson’s statistical significance threshold (0.05) and the number of 
apparently independent association tests in the human genome. It is estimated that in 
individuals of European ancestry there are about 1 million uncorrelated (“independent”) 
common SNPs, hence, the resulting threshold is 5x10-8 or 0.05 divided by 1 million. 
 
 
Pleiotropy: Describes a single genetic variant or multiple variants at the same locus that 
affect one or more phenotypic traits. If such genetic variation acts as possible underlying 
cause for an observed cross-phenotype association, then pleiotropy occurs [37].  
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65 T2D associated loci1 
 
45+1 CHD associated loci2,3 
Chromosome SNP Risk allele Nearest gene  SNP Risk allele Nearest gene 
        
Chr. 1 rs10923931 T NOTCH2  rs4845625 T IL6R 
 rs2075423 G PROX1  rs11206510 T PCSK9 
     rs602633 C SORT1 
     rs17114036 A PPAP2B 
     rs17464857 T MIA3 
Chr. 2 rs243021 A BCL11A  rs6544713 T ABCG5-ABCG8 
 rs780094 C GCKR   rs515135 G APOB  
 rs13389219 C GRB14   rs1561198 A VAMP5-VAMP8-GGCX 
 rs2943640 C IRS1 (2q36.3)  rs6725887 C WDR12  
 rs7593730 C RBMS1   rs2252641 G ZEB2-AC074093.1  
 rs11899863 C THADA   rs29436343 C 2q36.3 (1.61x10-7) 
Chr. 3 rs6795735 C ADAMTS9  rs9818870 T MRAS 
 rs11717195 T ADCY5     
 rs4402960 T IGF2BP2     
 rs1801282 C PPARG     
 rs12497268 G PSMD6     
 rs17301514 A ST64GAL1     
 rs7612463 C UBE2E2     
Chr. 4 rs6819243 T MAEA  rs1878406 T EDNRA 
 rs1801214 T WFS1  rs7692387 G GUCY1A3 
Chr. 5 rs459193 G ANKRD55  rs7173743 T ADAMTS7 
 rs6878122 G ZBED3  rs273909 C SLC22A4-SLC22A5 
Chr. 6 rs10440833 A CDKAL1  rs10947789 T KCNK5 
 rs3734621 C KCNK16  rs4252120 T PLG 
 rs4299828 A ZFAND3  rs2048327 G SLC22A3-LPAL2-LPA 
     rs12190287 C TCF21 
     rs12205331 C ANKS1A 
     rs9369640 C PHACTR1 
Chr. 7 rs17168486 T DGKB  rs12539895 A 7q22 
 rs17867832 T GCC1  rs2023938 G HDAC9 
 rs4607517 A GCK  rs11556924 C ZC3HC1 
 rs849134 A JAZF1     
 rs13233731 G KLF14     
Chr. 8 rs516946 C ANK1  rs264 G LPL 
 rs3802177 G SLC30A8  rs2954029 A TRIB1 
 rs7845219 T TP53INP1     
Chr. 9 rs10965250 G CDKN2A/B (9p21.3)  rs579459 C ABO  
 rs10758593 A GLIS3   rs1333049 C CDKN2BAS1 (9p21.3)  rs16927668 T PTPRD   rs3217992 A 
 rs2796441 G TLE1     
 rs13292136 C TLE4     
Chr. 10 rs12779790 G CDC123/CAMK1D  rs2505083 C KIAA1462 
 rs5015480 C HHEX/IDE  rs501120 A CXCL12  rs7903146 T TCF7L2  rs2047009 C 
 rs12242953 G VPS26A  rs12413409 G CYP17A1, CNNM2, NT5C2 
 rs12571751 A ZMIZ1  rs11203042 T LIPA      rs2246833 T 
Chr. 11 rs1552224 A ARAP1 (CENTD2)  rs974819 A PDGFD 
 rs2334499 T DUSP8  rs9326246 C ZNF259, APOA5, APOA1 
 rs5215 C KCNJ11     
 rs163184 G KCNQ1     
 rs10830963 G MTNR1B     
Chr. 12 rs11063069 G CCND2  rs3184504 T SH2B3 
 rs1531343 C HMGA2     
 rs12427353 G HNF1A (TCF1)     
 rs10842994 C KLHDC5     
 rs4760790 A TSPAN8/LGR5     
Chr. 13 rs1359790 G SPRY2  rs9515203 T COL4A1, COL4A2      rs4773144 G 
     rs9319428 A FLT1 
Chr. 14     rs2895811 C HHIPL1 
Chr. 15 rs2028299 C AP3S2  rs17514846 A FURIN-FES 
 rs4502156 T C2CD4A     
 rs7177055 A HMG20A     
 rs12899811 G PRC1     
 rs11634397 G ZFAND6     
Chr. 16 rs7202877 T BCAR1     
 rs9936385 C FTO     
Chr. 17 rs4430796 G HNF1B (TCF2)  rs12936587 G RASD1, SMCR3, PEMT 
 rs2447090 A SRR  rs2281727 C SMG6 
     rs15563 C UBE2Z 
Chr. 18 rs11873305 A MC4R     
Chr. 19 rs10401969 C CILP2  rs1122608 G LDLR 
 rs8108269 G GIPR  rs445925 C ApoE-ApoC1 
 rs8182584 T PEPD  rs2075650 G 
Chr. 20 rs4812829 A HNF4A     
Chr. 21     rs9982601 T KCNE2 
   
Table 2 - List of currently known T2D- and CHD-associated SNPs from most recent 
GWAS1,2,3, labelled according to the nearest the index SNP. 
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Table 3 – Associations of 55 confirmed glycaemic loci with T2D and/or 
cardiometabolic traits. 
 
 
Glycaemic traits 
 
p<5x10-8 
 
T2D 
 
p<10-4 
 
Lipids  
 
p<10-4  
 
Anthropometric 
measures 
p<10-4 
 
Nearest  
gene(s) Chr FI FG 2hGlu  Tg HDL-C BMI  WHR 
          
GRB14 2 +   + + -  + 
IRS1 2 +   + + -   
PPARG 3 +   +  -   
ANKRD55-MAP3K 5 +   + +   - 
ARL15 5 +   +   -  
FTO 16 +   +  - +  
PEPD 19 +   +  -   
LYPLAL1 1 +       + 
YSK4 2 +        
TET2 4 +        
PDGFC 4 +     -   
FAM13A 4 +     -   
UHRF1BP1 6 +        
RSPO3 6 +       + 
HIP1 7 +      +  
IGF1 12 +        
PPP1R3B 8 + + +   -   
GCKR 2 + + + + +    
TCF7L2 10 + + + +     
IGF2BP2 3  + + +     
ADCY5 3  + + +     
GCK 7  + + +     
VPS13C-C2CD4A/B 15  + + +     
GIPR 19  + + +   -  
PROX1 1  +  +     
ZBED3 5  +  +     
CDKAL1 6  +  +     
DGKB-TMEM195 7  +  +     
SLC30A8 8  +  +     
CDKN2B 9  +  +     
GLIS3 9  +  +     
MTNR1B 11  +  +     
ARAP1 11  +  +     
KL 13  +  +     
TOP1 20  +  +     
DPSYL5* 2  +   -    
G6PC2 2  +       
AMT 3  +       
SLC2A2 3  +       
PCSK1 5  +       
RREB1 6  +       
GRB10 7  +       
IKBKAP 9  +       
DNLZ 9  +       
ADRA2A 10  +       
CRY2 11  +       
OR4S1* 11  +       
MADD 11  +       
FADS1 11  +   - +   
GLS2 12  +       
P2RX2 12  +       
PDX1 13  +       
WARS 14  +       
FOXA2 20  +       
ERAP2 5   +      
 
 
Adapted from Scott RA et al. Nat. Genet. 2012 – PMID: 22885924 and from *Manning AK et al. Nat. Genet. 2012 – 
PMID: 22581228. The 55 loci harboring one or more allelic variants associated with glycaemic traits are shown 
according to the nearest known gene(s). +/-, effect direction of the glycemic trait raising allele; T2D, type 2 diabetes; 
Tg, triglycerides; HDL-C, HDL-cholesterol; BMI, body mass index (Kg/m2); WHR, waist-to-hip ratio; FI, fasting 
insulin; FG, fasting glucose; 2hGlu, 2-hour post-challenge plasma glucose concentration. 
 					
39 
Figure 1. Overlapping associations among currently known T2D, CHD and 
glycaemic quantitative trait susceptibility loci from recent GWAS. 
 
Loci harboring one or more common variant(s) associated with the phenotype or trait of 
interest are listed according to the nearest known gene. The diagram highlights the 
overlapping associations among A, B and C sets. Set A, coloured in yellow, comprises 65 
confirmed type 2 diabetes (T2D) susceptibility loci, from 1Morris A.P. et al. 
(DIAGRAMv3 Consortium) Nat. Genet. 2012 (PMID: 22885922) [14]. Set B (red) shows 
the 45 confirmed coronary heart disease (CHD) susceptibility loci from 2Deloukas P. et al. 
(CARDIoGRAMplusC4D Consortium) Nat. Genet. 2013 (PMID: 23202125) [15]. Set C 
(blue) shows the 55 confirmed loci associated with glucose- and insulin-related traits 
(fasting glucose, fasting insulin, 2 hour post-challenge glucose), from 3Scott R.A. et al. 
Nat. Genet. 2012 (PMID: 22885924) [12] and 4Manning A.K. et al. Nat. Genet. 2012 
(PMID: 22581228) [22]. 
The intersection between set A and set C comprises 34 loci associated with both T2D (at 
p<0.05 or lower) and glycaemic quantitative traits (p<5x10-8); loci reaching genome wide 
significance for association with both T2D and quantitative traits are marked by an 
asterisk (*).   
 
Chromosome 2q36.3- IRS1 is a starred locus also linked with detrimental levels of other 
cardiometabolic traits (for instance, higher triglycerides-to-HDL cholesterol ratio or low 
subcutaneous-to-visceral fat ratio) and harboring a variant (rs2943634) strongly 
associated with increased CHD risk (p=1.61x10-7, Samani NJ et al. NEJM 2007-PMID: 
17634449) [11]. The chromosome, 2q36.3-IRS1 locus, lying at the convergence of A, B 
and C sets, is a joint T2D_CHD locus. 
Chromosome 9p21.3 is a locus at the intersection of A and C sets characterized by two 
contiguous but distinct haplotype blocks harboring variants associated with T2D or CHD 
and separated by a recombination peak. A potential overlap of a T2D SNP lying in the 
CHD block at 9p21.3 makes this locus a promising candidate for a shared genetic risk for 
both T2D and CHD.   	
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Figure 2: Linkage Disequilibrium Patterns Among Lead SNPs at Type 2 
diabetes – Coronary Heart Disease Loci on Chromosomes 2 and 9 
  
The left-hand y-axis of each panel indicates the linkage disequilibrium (LD), represented 
by the r2 value, among single nucleotide polymorphisms (SNPs) at the locus, with the 
brightness of each point proportional to the r2 value for that SNP. The right-hand y-axis 
indicates the recombination rate, plotted as the blue line, with high values indicating 
frequent recombination at that spot on the chromosomal position, plotted as the x-axis in 
each panel. LD data come from sequence-based SNP genotype data from the low-
coverage sequencing pilot (Pilot 1) of the 1000 Genomes Project. This data set uses 
phased genotypes for 179 individuals from the HapMap CEU, YRI and JPT+CHB panels. 
Inter-SNP distances are measured in hg18 coordinates. Data were plotted using SNAP 
(Johnson A.D. et al., Bioinformatics 2008-PMID: 18974171 [49]). 
  
The top panel illustrates the chromosome 2q36.3 (left hand panel) and the IRS1 (right 
hand panel) locus. At 2q36.3, the SNP rs2943634 is in high LD with SNPs rs2943641, 
rs2943650, rs2943645 and rs2972146 (associated with coronary heart disease (CHD), 
type 2 diabetes (T2D), fasting insulin, waist circumference and triglyceride/HDL 
cholesterol ratio, all r2 >0.75), but in low LD with rs10167219 (ankle brachial index, 
r2=0.05). At IRS1, SNP rs1801278 (CHD, insulin resistance) is ~593kb from rs2943634 
and not in LD with any 2q36.3 SNP. Note the low LD and scarcity of SNPs in and around 
IRS1, indicating relatively high conservation (low variation) of base pairs around this 
important gene.  
  
The bottom panel illustrates the chromosome 9p21.3-CDKN2A/B locus, with the region 
of SNPs associated with CHD (left hand panel) separated from the region of SNPs 
associated with T2D (right hand panel) by a large recombination peak (blue line). The 
lead SNP for CHD (rs1333049) is only ~8.6kb from but essentially uncorrelated with the 
lead SNP for T2D (rs10811661, r2=0.009). However, a potential additional SNP 
associated with T2D, rs944801, lies in the CHD region and is modestly correlated with 
rs1333049 (r2=0.35), indicating a potentially joint T2D – CHD genetic region upstream 
from the CDKN2A/B genes. 
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Genetic Risk Score With Markers of Subclinical 
Atherosclerosis: A Transethnic, Multicenter Study 
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3.1 ABSTRACT 
 
English 
Background - Type 2 diabetes (T2D) and cardiovascular disease (CVD) share 
risk factors and subclinical atherosclerosis (SCA) predicts events in those with 
and without diabetes. T2D genetic risk may predict both T2D and SCA. The 
hypothesis tested in this research project was that greater T2D genetic risk is 
associated with higher extent of SCA.  
Methods and Results - In a cross-sectional analysis including up to 9,210 
European Americans, 3,773 African Americans, 1,446 Hispanic Americans and 
773 Chinese Americans without known CVD and enrolled in the FHS, CARDIA, 
MESA and GENOA studies, a 62 T2D-loci genetic risk score (GRS62) was tested 
for association with measures of SCA, including coronary artery (CACS) or 
abdominal aortic calcium score (AACS), common (CCA-IMT) and internal (ICA-
IMT) carotid artery intima-media thickness, and ankle-brachial index (ABI). 
Ancestry-stratified linear regression models were used, with random effects 
accounting for family relatedness when appropriate, applying a genetic-only 
(adjusted for sex) and a full SCA risk factors adjusted model (significance = p < 
0.01 = 0.05/5, number of traits analyzed). An inverse association with CACS in 
MESA Europeans (fully adjusted p=0.004) and with CCA-IMT in FHS (p=0.009) 
was not confirmed in other study cohorts, either separately or in meta-analysis. 
Secondary analyses showed no consistent associations with β-cell and insulin 
resistance sub-GRS in FHS and CARDIA. 
Conclusions - SCA appears unlikely to have a major genetic component linked to 
a burden of 62 T2D loci identified by large genome-wide association studies. A 
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shared T2D-CVD genetic basis, if any, might become apparent from the 
functional annotation of both T2D and CVD risk loci. 
 
Italian 
Premesse - Diabete mellito tipo 2 (T2D) e malattie cardiovascolari (CVD) sono 
fortemente associati clinicamente e condividono fattori di rischio che esercitano il 
loro effetto già a livello subclinico.  Ampi studi di associazione “genome-wide” 
hanno individuato numerosi loci di rischio per T2D, molti dei quali associati in 
particolare a indici di funzione beta-cellulare o resistenza insulinica (IR). Esiste 
inoltre una certa sovrapposizione tra loci associati a iperglicemia subdiabetica e 
iperinsulinemia e fenotipi intermedi di IR che sono anche fattori di rischio per 
CVD. Non è tuttavia chiaro se la predisposizione genetica a sviluppare T2D 
agisca quale comune denominatore per lo sviluppo di T2D e aterosclerosi 
subclinica (SCA).  
Obiettivo - In questo studio è stata testata l’ipotesi che un numero incrementale di 
varianti genetiche di rischio per T2D confermate dai più recenti studi di 
associazione genome-wide sia associato con aumentati valori di alcuni indici di 
SCA. 
Disegno sperimentale - In un’analisi trasversale di 9,210 Europei Americani, 
3,773 Africani Americani, 1,446 Ispanici Americani e 773 Cinesi Americani con 
anamnesi negativa per CVD ed arruolati negli studi FHS (Framingham Heart 
Study), CARDIA (Coronary Artery Risk Development in Young Adults), MESA 
(Multi-Ethnic Study of Atherosclerosis) e GENOA (Genetic Epidemiology 
Network of Atherosclerosis), è stata verificata l’associazione tra misure di SCA 
(calcium score coronarico e in aorta addominale, spessore intima-media in 
carotide comune ed interna, indice caviglia-braccio) ed uno score di rischio 
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genetico (GRS) composto da 62 polimorfismi (tag-SNP) noti per essere associati 
ad aumentato rischio di T2D. Il livello di significatività statistica è stato posto a 
p<0.01 (p=0.05/5, il numero di indici SCA analizzati) per ciascuno dei modelli 
statistici utilizzati (modello base corretto per sesso; modello completo corretto per 
un ampio numero di fattori di rischio cardiovascolari). 
Risultati - Il GRS per T2D non è risultato significativamente associato con SCA. 
Un’associazione negativa tra GRS e calcium score coronarico in MESA (Europei 
Americani) e con spessore intima-media in carotide comune in FHS (p=0.004 e 
0.009, rispettivamente, modello completo) non ha trovato conferma nelle altre 
coorti.  
Conclusioni - Il rischio genetico per T2D rappresentato da 62 tag-SNP non è 
associato con SCA in differenti gruppi etnici, nonostante una dettagliata 
fenotipizzazione, un ampio campione ed un disegno sperimentale multicentrico. E’ 
possibile che le basi genetiche comuni del rischio di T2D e CVD possano essere 
chiarite quando saranno individuate le varianti funzionali all’interno dei loci 
marcati dai 62 tag-SNP. 
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Abbreviations 
 
FHS   The Framingham Heart Study 
CARDIA  The Coronary Artery Risk Development in Young Adults 
MESA   The Multi-Ethnic Study of Atherosclerosis 
GENOA   The Genetic Epidemiology Network of Arteriopathy 
T2D   Type 2 Diabetes 
IGT   Impaired Glucose Tolerance 
CVD   Cardiovascular Disease 
SCA   Sub-Clinical Atherosclerosis 
CACS   Coronary Artery Calcium Score 
AACS   Abdominal Aortic Calcium Score 
CCA-IMT  Common Carotid Artery Intima-Media Thickness 
ICA-IMT  Internal Carotid Artery Intima-Media Thickness 
ABI   Ankle-Brachial Index 
GWAS  Genome-Wide Association Study  
SNP   Single Nucleotide Polymorphism 
GRS   Genetic Risk Score 
IDF   International Diabetes Federation 
FG   Fasting Glucose 
FI   Fasting Insulin 
Tg   Triglycerides 
HDL-C  High Density Lipoprotein Cholesterol 
BMI   Body Mass Index 
WHR   Waist-to-Hip Ratio 
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3.2  INTRODUCTION 
3.2.1 Background 
Type 2 diabetes (T2D) and cardiovascular disease (CVD) are clinically associated 
in adults 1, 2 and are an increasing public health and economic scourge in the US 3, 
4 and worldwide5-7 (Figure 1-3). Better prevention strategies require 
comprehension of the constellation of risk factors and mediators underlying both 
T2D and CVD 8, 9.  
T2D and CVD share a common metabolic milieu (Figure 4) that triggers 
metabolic and vascular dysfunction starting at subclinical disease stages (Figure 
5) or even at birth 10 due to genetic and non-genetic risk factors. In particular, 
many recently identified common genetic variants increasing risk for T2D also 
are associated with CVD risk factors 11 (Figure 6) and so might also confer risk 
for subclinical atherosclerosis (SCA) 12.  
Recently, a set of 36 T2D single nucleotide polymorphisms (SNPs) previously 
identified in large genome-wide association studies (GWAS) as affecting T2D 
risk was found to be associated with an increased risk of cardiovascular 
complications in type 2 diabetic patients 2, 13. It has been shown that an additive 
genetic risk score (GRS62) comprised of 62 validated T2D-associated SNPs 14-17 is 
a validated predictor of incident T2D in European and African Americans18, 19. 
 
3.2.2 Objective 
The present work sought to test the hypothesis that the T2D genetic burden, as 
represented by the polygenic T2D GRS62, is also positively associated in cross-
sectional analyses with variation in measures of SCA, including coronary artery 
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(CACS) or abdominal aortic calcium score (AACS), internal (ICA-IMT) or 
common carotid artery intima-media thickness (CCA-IMT), and ankle-brachial 
index (ABI).  
To maximize the sample size a multicenter transethnic association study was 
conducted in large population samples from four studies currently ongoing across 
the US (Figure 7): the Framingham Heart Study (FHS), the Coronary Artery Risk 
Development in Young Adults (CARDIA) 20, the Multi-Ethnic Study of 
Atherosclerosis (MESA) 21, 22 and the Genetic Epidemiology Network of 
Arteriopathy (GENOA) 23, 24.  
 
 
 
3.3 METHODS 
3.3.1 Study populations  
The Offspring Cohort of the Framingham Heart Study  
Analyses were conducted for each measured SCA trait on a range of 1,111 up to 
2,822 participants of European ancestry from the Offspring Cohort of the FHS 13, 
25. Outcomes of interest and related clinical characteristics included in the present 
analyses were obtained at Offspring examination cycles 6 (for analyses of ICA-
IMT and CCA-IMT) and 7 (for CACS and AACS). ABI was measured between 
the two examinations and the covariates used in the analysis of ABI were from the 
examination with the closest date to the ABI evaluation. Details regarding clinical 
assessment of participants and technical information about imaging tests and 
indices calculations have been published previously 13, 25, 26.  
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The CARDIA Study 
Analyses were conducted for the available SCA traits on 816 African Americans 
and 1,635 European Americans enrolled in the CARDIA Study 20. Analyses were 
limited to participants whose genotype information and clinical and 
anthropometric characteristics were available for all predictors of interest. Data on 
SCA from follow-up visit at years 20 (ICA-IMT and CCA-IMT) and 25 (CACS) 
were used. 
 
The MESA Study 
The MESA Study was designed to prospectively evaluate the development and 
progression of atherosclerotic disease. The complete design and protocols of 
MESA have been published previously 22. The selection included individuals 
from the resident list of adults from the urban areas of the recruiting centers with 
emphasis on ethnic diversity. The present study included up to 2,526 participants 
of European ancestry, 1,611 African Americans, 773 Asian Americans and 1,446 
Hispanic Americans from examination year 1 (2000-2001). 
  
The GENOA Study 
The longitudinal Genetic Epidemiology Network of Arteriopathy (GENOA) 
Study is one of four networks in the NHLBI Family-Blood Pressure Program and 
aims to elucidate the genetics of target organ complications of hypertension 24. 
GENOA recruited European and African American sibships with at least 2 
individuals with clinically diagnosed essential hypertension before age 60 years. 
European Americans were recruited from the Rochester, MN Field Center and 
African Americans were recruited from the Jackson, MS Field Center. Current 
analyses were conducted on CACS measures and genotypes available for 969 
European Americans and 535 African Americans.  
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In all study cohorts, participants with a personal history of CVD defined as 
myocardial infarction, stroke, coronary angioplasty and/or amputation not due to 
injury, when applicable, were excluded from the analyses. 
 
3.3.2. Assessment of subclinical atherosclerosis (SCA) 
SCA measures were determined in a similar fashion in all studies by means of 
carotid ultrasonography intima-media thickness, subcategorized for common and 
internal carotid (CCA-IMT and ICA-IMT), computed tomography scan for CACS 
and AACS, and ABI for peripheral artery disease, as detailed elsewhere 13, 27-30. 
FHS and MESA study participants had measurements available for all five SCA 
traits. CARDIA participants had ICA-IMT, CCA-IMT 31 and CACS 32 
measurements available for analyses. Evaluation and interpretation of CACS 
measures in MESA were conducted as published elsewhere 32, 33. In GENOA, 
CACS was measured in European Americans with an Imatron C-150 electron 
beam CT (EBCT) scanner (Imatron Inc., South San Francisco, CA) using a 
previously described protocol 34. In GENOA African Americans, CACS was 
measured with standard scanning protocols developed as part of the NHLBI’s 
MESA and CARDIA studies 32.  
 
3.3.3 Genotyping 
Genotyping in FHS was conducted using the Affymetrix GeneChip Human 
Mapping 500K Array supplemented with the Affymetrix 50K array, while 
CARDIA and MESA Study participants were genotyped using the Affymetrix 
Genome-Wide Human SNP Array 6.0 (Santa Clara, California) 35. GENOA Study 
participants were genotyped on the Affymetrix Genome-Wide Human SNP Array 
6.0 (Affymetrix, 2007) or the Illumina Human 1M-Duo BeadChip (Illumina, 
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2010) at the Mayo Clinic, Rochester, MN. Quality control measures and 
imputation strategy for missing genotypes were extensively detailed in previous 
reports 19, 35-37 for both FHS and CARDIA samples, while complete information 
on genotyping and imputation quality of MESA and GENOA samples are 
available in the Appendix.  
 
 
3.4 STATISTICAL ANALYSIS  
The GRS in FHS and CARDIA European Americans was calculated as the sum of 
the number of risk alleles (0, 1, or 2) at each locus, weighted by its published 
effect size (natural log-transformed) from the DIAbetes Genetics Replication And 
Meta-analysis (DIAGRAMv3) 14. For CARDIA African Americans and for each 
MESA and GENOA ethnic group an unweighted GRS was used, calculated by 
summing the risk alleles across the loci. ICA-IMT, CCA-IMT, AACS, CACS, 
fasting insulin, triglycerides and HDL-cholesterol were log-transformed to reduce 
skewness. Descriptive data were expressed as mean ± standard error, if not 
otherwise indicated. Multivariable linear regression models were used for 
CARDIA and MESA cohorts. Multivariable linear regression models with 
random effect to account for family relatedness were used to test the association 
of an additive 62 T2D SNPs GRS (Appendix Table 1) with measures of SCA in 
FHS and GENOA. 
For each SCA trait models adjusted only for sex (genetic-only model) and for a 
comprehensive set of SCA risk factors (full model), were used as shown in 
Appendix Table 2. Principal components were also included in GENOA and 
MESA models to control for population stratification in each ethnic group. The 
fully-adjusted model included comprehensive CVD risk factors: sex, age, waist 
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circumference, body mass index (BMI), triglycerides, HDL-cholesterol, LDL-
cholesterol, fasting insulin, fasting glucose, systolic blood pressure (SBP), 
hypertension/diabetes and/or lipid medication, physical activity, smoking status, 
family history of T2D and/or CVD. SBP was excluded in the analysis for ankle-
brachial index (ABI) since ABI is calculated from SBPs at ankle and arm.  
Subsidiary analyses were conducted by using two subsets of the 62 T2D SNPs 
comprised of 20 tag-SNPs thought to be associated with beta-cell function (GRSβ) 
or 10 associated with insulin resistance (GRSIR) 19 in the FHS and CARDIA 
cohorts to further elucidate possible mechanistic pathways, testing the hypothesis 
that genetic risk for IR in particular would be associated with SCA.  
Post-hoc power calculations using QUANTO 1.2 software showed that for a 
sample size of 1,835 individuals, there was 80% power to detect association of 
GRS62 explaining 0.64% of the variance in SCA traits with type 1 error rate set at 
p < 0.01 (p = 0.05 divided by the number of traits (5) analyzed). There was 80% 
power to detect association of GRSβ and GRSIR each explaining 0.73% or more of 
the variance in SCA traits with type 1 error set at p < 0.005 (0.05/[5 traits x 2 
GRS]).  
In order to replicate the primary FHS analyses in European Americans and to 
verify whether they might be extended to different ancestral groups, association 
analyses of the GRS62 with CACS, ICA-IMT and CCA-IMT in CARDIA, MESA 
and GENOA cohorts were then conducted separately within each ethnicity. Then, 
association results from each cohort were meta-analyzed using a fixed effect 
approach, separately for European and African Americans, with a two-sided 
p<0.01 as threshold for significance.  
All statistical analyses were carried out with SAS 9.2 (SAS Institute Inc., Cary, 
NC, USA) and R 2.9.2 38.  
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3.5 RESULTS 
Up to 7,952 European Americans, 2,124 Africans Americans, 773 Asian 
Americans and 1,446 Hispanic Americans from four cohort studies were analyzed. 
Clinical and anthropometric features and measures of SCA traits are shown for 
each study cohort in Appendix Table 3 and Appendix Table 4.  
Overall, study participants were of a wide age and BMI range. Prevalence of 
diabetes and abdominal obesity was much higher in African Americans than in 
other ethnicities. Participant characteristics within each ethnic group were 
comparable across all cohorts with the proportion of males and females being 
equally distributed, except in GENOA African Americans where women 
comprised 74.2% of the participants. The T2D GRS62 was approximately 
normally distributed with a range from 48.3 to 83.3 in European Americans and 
from 46.8 to 83.2 in African Americans over all cohorts. African Americans in 
CARDIA had higher mean GRS than European Americans, while the opposite 
was the case in MESA and GENOA cohorts. In MESA Asian and Hispanic 
Americans the T2D GRS62 spanned, respectively, from 48.1 to 73.6 and from 48.5 
to 79.6 (Appendix Figure 1 and Appendix Figure 2). GRSβ and GRSIR were 
normally distributed and ranged from 12.2 to 31.9 and from 3.3 to 18.0 in FHS 
and CARDIA European Americans, respectively, while in CARDIA African 
Americans the GRSβ ranged from 13.2 to 28.4 and the GRSIR ranged from 5.0 and 
16.9 (Appendix Figure 2).  
The primary analyses in FHS showed a significant inverse association between 
GRS62 and CCA-IMT (p = 0.009, fully adjusted model), which was not replicated 
in CARDIA or MESA (Table 1) European Americans. In the MESA European 
Americans, there was evidence for a significant inverse association between 
GRS62 and CACS (p = 0.004, fully adjusted model), which was not replicated in 
other cohorts (Table 1). Lack of evidence for a significant association between 
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GRS62 and SCA was confirmed by meta-analyses of up to 12,983 individuals 
from four cohorts for the available SCA traits, i.e. CACS, CCA-IMT and ICA-
IMT (Figure 8). 
Supplemental analyses showed that ICA-IMT was negatively associated with 
GRSβ in FHS in the fully adjusted model (p = 0.007, Appendix Table 5), but the 
finding was not replicated in CARDIA European Americans. The GRSIR was not 
significantly associated with any of the SCA traits in any of the models in either 
the FHS cohort or in either CARDIA ethnic group (Appendix Table 6). 
 
 
3.6 DISCUSSION 
The primary finding of the present exercise was that there is no evidence of a 
statistically significant association between the genetic burden for T2D, based on 
a 62 T2D SNP GRS, and a wide set of subclinical atherosclerosis traits in a large 
US adult population sample. Results were consistent for all four ancestral groups 
studied. An inverse association of the GRS62 with CCA-IMT in FHS was not 
confirmed in two other cohorts either in replication comparisons or meta-analysis. 
A 10 SNP GRS and a 20 SNP GRS representing variants associated, respectively, 
with beta-cell function or insulin resistance also was not statistically significantly 
associated with SCA. Starting with the plausible hypothesis that T2D genetic risk 
would also be associated with SCA, a rigorous approach was applied including 
conservative correction for multiple trait tests, replication studies in separate 
cohorts (thereby reducing type 1 error) and meta-analysis of a sufficiently large 
sample size (increasing power). It can be therefore conclusively stated that this 
particular formulation of T2D genetic risk is not associated with higher indices of 
SCA in the study participating in the present study. 
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These results can be compared to other recent studies. As recently highlighted 11, 
the genetic signatures of T2D, coronary heart disease and glycemic quantitative 
traits have some elements of commonality, though limited only to 2q36.3 and 
9p21.3 chromosomal regions. Notably, a major proportion of fasting insulin-
associated loci showed a directionally consistent association with T2D risk and 
CVD quantitative risk factors (i.e. adverse lipid profile and abdominal adiposity) 
but none of the glycemic quantitative traits appears to be directly associated with 
CVD-risk. While Qi et al. 2 showed that a GRS comprised of 36 T2D genetic 
variants was associated with an increased risk of CVD complications (a 
composite endpoint including fatal or nonfatal coronary heart disease and stroke) 
in European Americans affected by T2D, other attempts failed to identify an 
etiological link between SCA traits and T2D genetic variation at candidate 
2q36.3-IRS1 locus in the Framingham Heart Study 13. Additionally, while Doria et 
al.39 showed that the effect of genotype at 9p21.3 locus on CVD events is raised 
only in persons with T2D who have poor glycemic control, Rivera et al. 40 have 
recently shown that, compared to non-T2D individuals, a higher number of 
variants at 9p21.3 locus is associated with the severity of coronary artery disease 
comorbid with T2D. These lines of evidence suggest that T2D and non-T2D 
subjects might have different mechanisms leading to CVD events and that within 
T2D cases hyperglycemia might act as permissive environment leading to the full 
expression of CVD-risk genetics. These data, together with the null results of the 
present study, both with our full T2D GRS62 and with the two sub-scores (GRSIR 
and GRSβ), collectively suggest that in the general population T2D and CVD are 
not genetically linked together through SCA, the association of T2D genetics 
being so far observed only with CVD events but not with early subclinical disease. 
Strengths of the present exercise include a validated T2D GRS aligned to the 
current level of evidence, a detailed phenotypic characterization, a comprehensive 
selection of covariates, confounders and mediators, as well as a careful control of 
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type 1 and type 2 errors by means of a large sample size from the general 
population and a multicenter replication strategy in different ethnicities, as 
discussed above. Additionally, given the strong age-calcification relationship 
across young adulthood, mid-life and older ages 41, 42, the wide range of age 
among different cohorts allowed to capture the whole spectrum from early- to 
late-onset calcification.  
However, the approach proposed here might have been weakened by multiple 
interactions among different SNPs within the GRS: several of the component 
genes in the score may be indeed associated with SCA, but the component score 
might not be significantly associated if the effect was diluted by the other variants. 
Furthermore, the 62 genome-wide significant SNPs used explained only a fraction 
(around 10%) of the total T2D phenotypic variance in other studies 43 and did not 
represent actual functional allelic variants that have yet to be discovered. It should 
be also acknowledged that, if it is assumed that T2D contributes to CVD, 
excluding individuals with a personal CVD history might have resulted in a 
population enriched for protective factors especially among those with higher 
T2D GRS, which might also explain the borderline negative association of the 
GRS62 with CCA IMT in FHS and CACS in MESA European Americans.  
However, in preliminary sensitivity analyses conducted in FHS and CARDIA the 
T2D GRS62 allele distribution resulted to be comparable between people with 
positive personal CVD history and the population actually used in the association 
analyses (data not shown), so that, for consistency with the main focus of the 
present research on subclinical atherosclerosis individuals with clinical evidence 
of incident or prevalent CVD were excluded, as defined above in the Methods 
section. Lastly, while the GRS could be confidently used to depict the T2D 
genetic risk for European and Mexican Americans, and therefore reasonably 
allow to claim robustness of the obtained results, the GRS was not best tailored to 
fit T2D genetics in African or Asian Americans, given their different haplotype 
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structure and allele frequencies 37 and given that most of GWAS hits have been 
discovered and confirmed in people of European ancestry.  
Results of this research project have several implications and point to future 
directions.  The present study provided compelling evidence that the genetic 
burden of T2D risk as represented by this GRS62 formulation was not associated 
with SCA. This suggests that either T2D is not working as reasonable foundation 
of clinical CVD through SCA, at least at the genetic level, or that more complex 
formulation of T2D genetic risk might be associated with SCA, or that no large 
common genetic soil 12 underlies both T2D and CVD. 
However, T2D and SCA are strongly linked clinically 1, 2 and the prevalence of 
CVD events and the burden of CVD risk factors are higher in people with 
diabetes. Therefore, although the last decade has shown an increasing expansion 
in the understanding of the genetic signature of complex traits, new approaches 
incorporating functional, structural and/or regulatory annotation 44, 45 into disease 
prediction is needed to untangle the missing link, if any, between T2D and CVD 
at the genetic level. Furthermore, given that screening for SCA in asymptomatic 
individuals at intermediate CVD risk improves CVD risk stratification 46 and that 
current polygenic scores slightly but not remarkably outperform clinical models 18, 
functional interrogation of T2D and CVD genetic architecture is necessary to 
further optimize polygenic risk prediction of either T2D or CVD or both.  
 
3.7     CONCLUSIONS 
In conclusion, the present exercise places an additional step in the wider 
framework of CVD prediction and it is expected that it will serve as placeholder 
for future mechanistic investigations. Given the global burden of T2D and CVD 
 					
64 
in the era of precision medicine and prospective patient-oriented healthcare, it is 
timely to acquire additional knowledge about the genetic determinants of T2D, 
CVD and intermediate traits to improve risk prediction and the ability to discover 
newly targeted therapeutic molecules. 
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Figure 1 – Global projections for the diabetes epidemic 2010-2030 - IDF Diabetes Atlas 2011 
 
 
 
Figure 2 – Worldwide prospective prevalence (2010-2030) of diabetes and sub-threshold 
hyperglycemia (IGT, Impaired Glucose Tolerance) – IDF 2011 
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Figure 3 – Percent of medical condition-specific expenditures associated with diabetes in 
U.S.A. – American Diabetes Association 2013 
 
 
 
 
 
 
 
 
 
 
Figure 4 – CVD risk factors and the common T2D-CVD metabolic inflammatory milieu 
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Adapted from Lorber D. et al. Diabetes Metab. Syndr. Obes. 2014 
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Figure 5 – Atherosclerosis is higher in type 2 diabetes but also in intermediate, insulin 
resistant (IR) phenotypes: The Framingham Offspring Study. 
 
 
 Modified from Meigs et al. Diabetes Care 2002 
 
 
Figure 6 – Association of some glycaemic traits loci with type 2 diabetes and/or insulin 
resistance-associated metrics overlapping coronary heart disease risk factors. 
 
Locus Chr T2D 
P<-E04 
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GRB14 2       
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Modified from Scott et al. Nat. Genet. 2012 
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Figure 6 – Meta-analysis of GRS62 association testing with CACS, CCA-IMT, ICA-IMT 
measures across all study cohorts stratified by European and African Americans. 
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Figure 6 Legend 
CACS (panel-A, Nmeta=4,780; panel-B, Nmeta=1,835), CCA-IMT (panel-C, Nmeta=6,220; panel-D, Nmeta=2,190), 
ICA-IMT (panel-E, Nmeta=5,842; panel-F, Nmeta=2,109); GRS62, genetic risk score comprised of 62 single 
nucleotide polymorphisms associated with type 2 diabetes; CACS, coronary artery calcium score; CCA-IMT 
and ICA-IMT. 	
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Chapter 4 
 
 
Is common genetic variation at IRS1, ENPP1 and TRIB3 
loci associated with cardiometabolic phenotypes in type 2 
diabetes? An exploratory analysis of the Verona Newly 
Diagnosed Type 2 Diabetes Study 
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4.1 ABSTRACT 
 
English 
Background and Aims - Insulin resistance is a hallmark of type 2 diabetes 
(T2DM), it is often accompanied by defective beta-cell function (BF) and is 
involved in the pathophysiology of cardiovascular disease (CVD). Commonalities 
among these traits may recognize a genetic background, possibly involving the 
genetic variation of insulin signaling pathway genes. We conducted an 
exploratory analysis by testing whether common genetic variability at IRS1, 
ENPP1 and TRIB3 loci is associated with cardiovascular risk traits and metabolic 
phenotypes in T2DM. 
 
Methods and Results - In 597 drug-naïve, GADA-negative, newly-diagnosed 
T2DM patients we performed: 1) genotyping of 10 independent single-nucleotide 
polymorphisms covering ~90% of common variability at IRS1, ENPP1 and 
TRIB3 loci; 2) carotid artery ultrasound; 3) standard ECG (n=450); 4) 
euglycaemic insulin clamp to assess insulin sensitivity; 5) 75g-OGTT to estimate 
BF (derivative and proportional control) by mathematical modeling. False 
discovery rate of multiple comparisons was set at 0.20. After adjustment for age, 
sex and smoking status, rs4675095-T (IRS1) and rs4897549-A (ENPP1) were 
significantly associated with carotid atherosclerosis severity, whilst rs7265169-A 
(TRIB3) was associated with ECG abnormalities. Rs858340-G (ENPP1) was 
significantly associated with decreased insulin sensitivity, independently of age, 
sex and body-mass-index. No consistent relationships were found with BF.  
 
Conclusions - Some associations were found between intermediate phenotypes of 
CVD and common genetic variation of gatekeepers along the insulin signaling 
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pathway. These results need be replicated to support the concept that in T2DM the 
CVD genetic risk clock may start ticking long before hyperglycemia appears. 
 
 
 
Italian 
Premesse e Scopo - L’insulino-resistenza (IR) è una caratteristica peculiare del 
diabete tipo 2 (DMT2), è coinvolta nella fisiopatologia delle malattie 
cardiovascolari (CVD) e spesso si accompagna ad una compromessa funzione 
beta-cellulare (BF). In questo contesto, è possibile che la variabilità genetica 
comune di alcuni geni coinvolti nella cascata del segnale insulinico possa spiegare, 
almeno in parte, la relazione esistente tra DMT2, CVD e BF. In questo studio 
abbiamo pertanto cercato di verificare se la variabilità genetica comune dei loci 
IRS1, ENPP1 e TRIB3 è associata a tratti di rischio cardiovascolare e fenotipi 
metabolici in soggetti affetti da DMT2 arruolati nel Verona Newly Diagnosed 
Type 2 Diabetes Study (VNDS).  
 
Metodi e Risultati - In 597 soggetti con DMT2 neodiagnosticato, privi di 
trattamento farmacologico e con negatività degli anticorpi anti-GAD sono stati 
effettuati: 1) genotipizzazione di 10 polimorfismi indipendenti e selezionati per 
catturare il 90% della variabilità  genetica comune dei loci IRS1, ENPP1 e TRIB3, 
noti quali principali regolatori della cascata del segnale insulinico; 2) eco-Doppler 
carotideo; 3) ECG standard (n=450); 4) clamp euglicemico iperinsulinemico, 
gold-standard per la determinazione della sensibilità insulinica; 5) stima della BF 
con modello matematico nelle sue componenti derivativa e proporzionale. Dopo 
correzione per età, sesso e abitudine tabagica i polimorfismi rs4675095-T (IRS1) 
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and rs4897549-A (ENPP1) sono risultati significativamente associati a più severa 
aterosclerosi carotidea, mentre rs7265169-A (TRIB3) era associato ad anormalità 
ischemiche dell’ECG. Dopo correzione per età, sesso e indice di massa corporea, 
rs858340-G (ENPP1) era significativamente associati a maggiore IR; non è stata 
rilevata nessuna relazione significativa tra BF ed i polimorfismi in studio.  
 
Conclusioni - La variabilità genetica comune dei principali geni regolatori della 
cascata del segnale insulinico potrebbe spiegare, almeno in parte, l’associazione 
tra IR e CVD nel DMT2. Benchè siano necessari studi di replicazione in più 
ampie coorti di soggetti, questi risultati suggeriscono che nel DMT2 il rischio 
genetico per CVD verosimilmente agisce ben prima che il fenotipo clinico 
dell’iperglicemia si manifesti ed esercita i propri effetti sul fenotipo cardio-
metabolico sin dalle fasi più precoci della malattia diabetica.  
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4.2 INTRODUCTION 
 
Insulin resistance (IR) and its associated traits may act as a common soil for both 
type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) [1, 2]. The 
genetic annotation of hitherto confirmed allelic variants associated with the risk of 
T2DM and CVD is hoped to unveil mechanistic explanations at the genetic level 
of the strong clinical link existing between these highly prevalent complex traits 
[3]. 
Some non-synonymous allelic variants harbored in or near insulin signaling 
pathway genes, namely ENPP1 (ectonucleotide 
pyrophosphatase/phosphodiesterase 1), IRS1 (insulin receptor substrate 1) and 
TRIB3 (tribble homolog 3), have raised considerable interest [4-6] given their 
association with defective insulin action and impaired endothelial cell function.  
The very same variants have been recently confirmed as jointly increasing the 
CVD risk [5], possibly by affecting systemic and endothelial insulin sensitivity [4, 
5]. In vitro [7, 8] and in vivo studies [4, 5, 9] showed that ENPP1 K121Q 
(rs1044498), IRS1 G972R (rs1801278) and TRIB3 Q84R (rs2295490) are 
associated with an increased risk of T2DM and CVD through their effect on the 
endothelial nitric oxide synthase and the fibrinolysis system. However, other 
studies on the same loci found no significant association with T2DM or 
intermediate CVD risk traits [10, 11].  
Thus, some evidence supports the association of non-synonymous genetic variants 
of IRS1, TRIB3 and ENPP1 with overall CVD risk, but their clinical applicability 
to unambiguously identify high-risk subjects remains a still unanswered question. 
IRS1, ENPP1, TRIB3 loci have been associated with CVD and T2DM risk based 
upon findings related to non-synonymous variants entailing changes of protein 
function. Genes harboring mutations resulting in rare monogenic disorders often 
have been found to be involved in the genetic risk of common complex disorders 
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through common variants, a most striking example being the role played by some 
MODY genes on T2DM pathogenesis [12]. We hypothesized that something 
analogous might occur also at IRS1, ENPP1, TRIB3 loci. Indeed, their actual role 
may be wider than the one suggested by their non-synonymous variants and may 
be due also to common variability. Therefore, we conducted an exploratory 
analysis in the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) of 13 
common polymorphisms, selected to comprehensively capture the genetic 
variation at three candidate loci (ENPP1, IRS1 and TRIB3) previously reported as 
being associated with the insulin signaling cascade. We investigated whether they 
are individually associated with one or more of four (4) outcome traits, including 
ECG ischemic abnormalities and subclinical atherosclerosis readouts at common 
carotid artery as representative of the “cardiovascular” domain, and insulin 
resistance (IR) and beta cell function (BF), as representative of the “metabolic” 
domain. 
 
 
 
 
 
4.3 METHODS 
 
4.3.1 Study population 
The VNDS is an ongoing study aimed at building a biobank of patients with 
newly-diagnosed T2DM. A detailed description of the overall experimental 
approach have been previously published [13] and is available in the online 
Supplementary Material. The research was approved by the Human 
Investigation Committee of the Verona City Hospital. Each subject signed a 
written informed consent upon recruitment. 
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4.3.2 Genotyping 
Thirteen independent tag-SNPs of IRS1 (rs4675095 and rs1801278), ENPP1 
(rs6939185, rs858340, rs1044498, rs9493119, rs4897549) and TRIB3 (rs6076472, 
rs6139007, rs7265169, rs2295490, rs12626158, rs6115830) loci were selected to 
capture at least 90% of the common genetic variability (Supplementary Fig. S1) 
by GEVALT (GEnotype Visualization and ALgorithmic Tool) software. A 
peripheral blood sample was collected from each patient and DNA was extracted 
by standard salting-out method. Genotypes were assessed by Veracode technique 
(Illumina Inc, CA), applying the GoldenGate Genotyping Assay according to 
manufacturer’s instructions. The selected SNPs were in low linkage 
disequilibrium (LD), with r2 between the SNPs at each locus comprised between 
0.0 and 0.16. Further information are provided in Supplementary Figure S1 and 
Supplementary Table S3. Ten SNPs were successfully genotyped (rs4675095, 
rs1801278, rs6939185, rs858340, rs9493119, rs4897549, rs6076472, rs6139007, 
rs7265169, rs6115830) in all study participants. Genotyping of rs1044498, 
rs2295490 and rs12626158 failed due to technical issues. None of them was in 
LD with other genotyped SNPs at the same loci, as provided in Supplementary 
Table S3, so that it was not possible to replace them with other highly correlated 
SNPs in the association analyses. 
 
 
4.3.3 Cardiometabolic Phenotyping 
A standard 12-lead electrocardiogram (ECG) was performed in 450 study 
participants (CardioDirect 12 unit; Metasoft 3.9 software). Presence of ischemic 
abnormalities was recorded according to Minnesota code and categorized as 
suggestive for “definite”, “probable” or “possible” coronary heart disease (CHD) 
[14].  
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High-resolution B-Mode echo-color Doppler of common carotid artery was 
performed by a single operator in 597 subjects with a 10-MHz linear probe with 
axial resolution of 0.01 mm (Esaote Wall Track System, Esaote S.p.A., Genova, 
Italy). Common carotid intima-media thickness (CC-IMT) was estimated by 
scanning the posterior wall of common carotid artery at 1 cm from carotid 
bifurcation. Patients were classified in three categories: no carotid atherosclerosis; 
impaired CC-IMT and/or stenosis <40%, stenosis >40%. The cutoff of 40% was 
adopted based on previous experience [15]. 
Blood pressure was measured at the upper left arm in all subjects and classified 
according to 2013 ESH/ESC guidelines. 
Metabolic tests were carried out on two separate days in random order. On one 
day a frequently sampled, prolonged (240 or 300 min) OGTT (75 g) was 
performed and beta-cell function (BF) was reconstructed by mathematical 
modeling, as previously described [16]. By this method, BF is described by two 
parameters: 
1. Derivative (or dynamic) control (DC): the response of the beta cell to the 
rate of increase of plasma glucose; 
2. Proportional (or static) control (PC): the response of the beta cell to 
glucose concentration per se. 
On a separate day, a euglycaemic insulin clamp was performed to assess insulin 
sensitivity [13].  
Beta cell modeling and clamp derived insulin sensitivity can be considered 
reference methods to assess insulin secretion and action in vivo in man. However, 
to facilitate the comparison with widely used OGTT-derived surrogate indexes, 
we also report the insulinogenic index, the corrected insulin response and the 
Matsuda Index of insulin sensitivity (see below) in the Supplemental Material.  
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4.3.4 Analytical Methods 
Plasma glucose was measured in duplicate with a Beckman Glucose Analyzer II 
(Beckman Instruments, Fullerton, CA, USA) or with an YSI 2300 Stat Plus 
Glucose&Lactate Analyzer (YSI Inc., Yellow Springs, OH, USA), at bedside. 
Serum C-peptide and insulin were measured by chemiluminescence [13]. GAD-
antibodies were measured by immunoradiometry (CentAK, Medipan, Germany); 
glycosylated haemoglobin and serum lipids by standard in-house methods. 
 
 
4.3.5 Calculations 
The amount of glucose metabolized during the last 60 min of the clamp (M-value, 
reference insulin sensitivity; units: µmol/min/m2 BSA) was computed with 
standard formulae [16].  
Mathematical modeling of glucose and C-peptide time series following the 75-g 
oral glucose challenge were performed and DC and PC of BF were computed, as 
previously described [13]. Modeling details are found in the Supplemental 
Material. 
The following OGTT-derived indices were also computed and are reported in the 
Supplemental Material:  
1. Insulinogenic Index: (Insulin30’ – Insulin0’)/(Glucose30’ - Glucose0’); units: 
mU/mmol;  
2. Corrected Insulin Response at time 120’ of the OGTT (CIR120’): 
Insulin120’/[Glucose120’⋅(Glucose120’ - 3.89)]; units: mU⋅L/mmol2;  
3. Matsuda Index of insulin sensitivity: 10,000/[(Glucose0’⋅Insulin0’)⋅(Mean 
OGTT glucose concentration)⋅(mean OGTT insulin concentration)]1/2. 
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4.4 STATISTICAL ANALYSIS 
 
Data are presented as median and interquartile range, unless otherwise indicated. 
Hardy-Weinberg equilibrium was tested by chi-square test. For each SNP, the 
allele with the lowest occurrence in our population was considered as the effect 
allele in the analyses according to an additive model of inheritance. Statistical 
models were unadjusted (M1) or adjusted (M2) for relevant covariates (age, sex 
and smoking status for cardiovascular readouts, or age, sex and BMI for 
metabolic readouts). Logistic regression models were applied to test the 
association between genotypes and cardiovascular phenotypes (outcome traits: 
carotid artery atherosclerosis, ECG ischemic abnormalities). Only a genetic 
additive model was tested. Generalized Linear Models, as implemented in the 
SPSS software, with or without repeated measures as appropriate, were carried 
out to test the associations between genetic variability and metabolic traits (log-
transformed or square-root transformed, if needed, unless the latter displayed 
strong deviation from the Gaussian distribution which could not be corrected by 
transformation. In the latter case, which applied only to DC of BF, non-parametric 
(Kruskal-Wallis) tests were applied with no correction for covariates).  
Since the present study is an exploratory analysis, the control of the family wise 
error rate (FEW) of 50 multiple comparisons (10 SNPs by 5 outcome variables: 
ECG, carotid atherosclerosis, clamp-assessed insulin sensitivity and DC and PC 
of BF), according to Bonferroni’s correction, was deemed too conservative. Thus, 
we applied the two stage step-up linear procedure of Benjamini-Krieger-Yekutieli 
(BKY) [17], a recent evolution of the Benjamini-Hochberg’s method, to control 
the false discovery rate (FDR) (see Supplemental Material for details). 
Selections of FDRs ranging from 0.25 to 0.05 can be found in previous papers, 
the lower figure being conceptually analogous to Bonferroni’s correction in 
strongly favouring protection against false positive results vs. the risk of declaring 
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false negative findings. We selected an FDR of 0.20, the highest acceptable FDR 
according to Benjamini and Yekutieli [18] in line with the exploratory nature of 
this work. All statistical tests were performed by the SPSS 22.0 software. 
 
 
4.5 RESULTS 
In this study we report the data collected in 597 VNDS patients: anthropometric, 
clinical and metabolic features are summarized in Table I. Ten independent SNPs 
were successfully genotyped and were all in Hardy-Weinberg equilibrium (Table 
II). Rs1044498, rs2295490 and rs12626158 were not included in the statistical 
analyses due to poor quality genotyping. 
At a FDR set at 0.20, the BKY procedure [17] rejected 5 null hypotheses, i.e. 
accepted 5 results as statistically significant. These are presented herein below. 
Other findings with nominal (i.e. p<0.05) statistical significance, but not rejected 
by BKY, are not presented.  
 
Rs4897549-A (ENPP1) and rs4675095-T (IRS1) were significantly associated 
with a greater severity of carotid atherosclerosis (p=0.01 and p=0.009, 
respectively), independently of age, sex and smoking status (Table III, panel A 
and B)). In a secondary analysis, rs4897549-A and rs4675095-T were jointly 
tested for independent association with the presence of carotid atherosclerosis 
(p=0.009 and p=0.014, respectively, Table III, panel D). Their associations with 
carotid atherosclerosis were confirmed to be independent with odd ratios almost 
superimposable to the ones found in the previous analysis. Rs7265169 (TRIB3) 
was associated with ECG ischemic abnormalities (Table III, panel C). 
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The G major allele of rs858340 in ENPP1 was significantly (p=0.008) associated 
with impaired insulin sensitivity (Figure 1). Furthermore, rs6939185 (ENPP1) 
was associated with altered derivative control of BF (p=0.024, by Kruskal-
Wallis). However, the derivative control (units: pmol per square meter of BSA; 
median [I.Q. range]) was 488 [105 - 1054] in rs6939185 GG carriers, 377 [0 - 
821] in AG carriers and 565 [125 - 1187] in AA carriers. Thus, the relationship 
appeared biologically inconsistent and will not be discussed further.  
 
 
 
4.6  DISCUSSION 
 
In this study we explored the possible associations of common genetic variation in 
or near three loci harboring insulin signaling pathway genes with cardiometabolic 
phenotypes in a well-characterized sample of patients with newly-diagnosed 
T2DM. Since diabetes itself is equipotent to previous stroke or MI in determining 
mortality risk, we selected for our analysis the two metabolic phenotypes, i.e. 
insulin sensitivity and beta cell function (BF), which are at the core of the 
pathophysiology of T2DM, and two cardiovascular intermediate phenotypes 
(ECG and carotid artery ultrasound scan) which are in widespread clinical use.  
On the genetic side, given the role of insulin action in many cells involved in 
atherogenesis, we assessed the common genetic variability of three known 
gatekeepers of insulin signaling, ENPP1, IRS1 and TRIB3, previously associated 
with cardiovascular risk and/or intermediate phenotypes through their non-
synonymic variants.  
We report that rs4897549 (ENPP1) and rs4675095 (IRS1) were independently 
associated with increased carotid atherosclerosis (Table III, panel A and B and 
 					
91 
D), while rs7265169 (TRIB3) was associated with ECG ischemic abnormalities 
(Table III, panel C). Interestingly, previous in vitro studies suggested that 
alterations in insulin pathway genes promote endothelial dysfunction, hence 
predisposing to CVD [19, 20]. Additionally, while previous studies showed that 
the non-synonymic ENPP1 K121Q, IRS1 G972R and TRIB3 Q84R variants were 
associated with cardiovascular events in human subjects [19-21], our findings 
support the hypothesis that the variance of subclinical CVD risk traits may be 
explained to some extent also by common genetic variation in or near these loci as 
well.  
Rs858340 at ENPP1 was associated with insulin resistance (Figure 1), thus 
extending previous observations on the detrimental effect of ENPP1 genetic 
variability on insulin action [22]. Unfortunately, failure of rs1044498 (ENPP1) 
genotyping – for which a large body of literature exists [5, 9] – did not allow to 
directly test this specific variant against the outcome traits. Owing to the selection 
criteria used to pick up the SNPs for the current study it was impossible to replace 
rs1044498 with other nearby, highly-correlated SNPs (using a r2 threshold of 0.6, 
at the minimum). However, since the genetic variants selected for our analyses 
captured a large proportion of the genetic variability at each locus, our results 
further strengthen the message that multiple IR-associated variants are harbored 
within the LD block structure of ENPP1 locus.  
None of the variants at IRS1 and TRIB3 was associated with insulin resistance. 
This is in line with some studies on IRS1 G972R (rs1801278) conducted in T2DM 
and non-T2DM humans [23, 24]. However, a more extensive documentation in 
humans and rodents [25-27], although mostly based on surrogate insulin-
sensitivity indices, supports the negative effect of some IRS1 and TRIB3 variants 
on insulin sensitivity in vitro and in vivo. 
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Inspired by the case of some MODY genes, which harbour common genetic 
variants affecting T2DM risk [12], and by the primary role played by insulin 
secretion in the pathogenesis of T2DM, we tested the genetic variation of ENPP1, 
TRIB3 and IRS1 for association with BF. One polymorphism in ENPP1 
(rs6939185) showed a significant association with decreased derivative control of 
BF. However, its relationship to BF appeared to be biologically inconsistent. 
Indeed, our FDR threshold (0.20) is compatible with one out of 5 accepted 
findings being spurious. Thus, common genetic variability of ENPP1 was 
associated with both carotid atherosclerosis (through rs4897549) and insulin 
resistance (through rs858340). 
No significant relationships between common genetic variability of IRS1, or 
ENPP1 or TRIB3 and beta cell function could be claimed, in spite of some 
nominal statistical significance (data not shown). Previous in vitro and in vivo 
studies showed that ENPP1 and TRIB3 affect beta-cell survival [28, 29], thereby 
being potentially able to affect beta-cell mass. Indeed, the gain-of-function 
variants ENPP1 K121Q (rs1044498) and TRIB3 Q84R (rs2295490) increase beta 
cell apoptosis [20, 28]. However, no associations between changes in beta cell 
function and common genetic variability of these loci can be declared on the basis 
of our findings.  
Taken together, our exploratory analysis suggests that common genetic variability 
of ENPP1 may play a pivotal role in cardiometabolic phenotypes, in that it may 
be implicated in carotid atherosclerosis and insulin resistance. Genetic variability 
at IRS1 and TRIB3 may play independent roles in carotid atherosclerosis and 
ischemia-related alterations in ECG, respectively.  
The most important strength of our study is the use of state-of-art methods to 
assess insulin sensitivity and BF, instead of surrogate markers, in a large sample 
of patients with newly-diagnosed T2DM. Furthermore, study participants were 60 
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years old on average (enough to convey the effect, if any, of low-penetrance 
genetic determinants) and presumably not yet influenced by long-standing 
hyperglycemia or pharmacological glucose-lowering treatment, which could 
modify phenotype-genotype interaction.  
However, our study has some limitations: i- it is not a population based study, 
although the VNDS cohort is fairly representative of Italian patients with T2DM 
[14]; ii- the cohort includes a large number of men, possibly reflecting a gender-
related referral bias; iii- the relatively low number of patients may have limited 
the statistical power; iv- the absence of a replication cohort cautions against the 
generalizability of our findings. Therefore, we have consulted the publicly 
available MAGIC Consortium database looking for association results relative to 
surrogate indexes of insulin sensitivity (HOMA-IR, IR-Homeostatic Model 
Assessment and ISI, Insulin Sensitivity Index) and BF (HOMA-B, BF- 
Homeostatic Model Assessment and CIR30’, Corrected Insulin Response) [30, 31]. 
As a result, among the four relevant SNPs, rs4675095-A (IRS1) was negatively 
associated with HOMA-IR and HOMA-B (at p=1.17xE-04 and p=4.2x10E-3, 
respectively), while there was no robust association with ISI (p=0.08) or CIR30’ 
(p=0.94); rs858340-T (ENPP1) was nominally associated with lower HOMA-IR 
(p=0.031) but not with ISI (p=0.079) (Supplementary Table S6-S9). Among the 
other SNPs considered, it is worth to mention the positive association of 
rs6139007-T (TRIB3) with HOMA-IR (p=0.029) and the negative association of 
rs9493119-A (ENPP1) with CIR30’ (0.003). Hence, none of the results from our 
analysis was robustly replicated in the MAGIC database, which, once again, 
highlights both the intrinsic limitations of surrogate indexes and the relatively 
limited statistical power of our database.  
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4.7 CONCLUSIONS 
In summary, in this exploratory analysis, IRS1, ENNP1 and TRIB3, known to be 
associated with T2DM and harboring genes playing a prominent role in mediating 
insulin signaling, may modulate a number of cardiometabolic phenotypes in 
patients of Italian ancestry with newly-diagnosed T2DM. Although replication 
studies in separate deeply-phenotyped cohorts are needed to corroborate our 
results, our findings suggest that ENPP1 may be a genetic locus potentially 
implicated in the association both with insulin resistance in diabetes and with 
cardiovascular disease. Other gatekeepers of the insulin signaling pathway, 
specifically IRS1 and TRIB3, might play additive roles in the pathogenesis of 
cardiovascular complications in patients with T2DM. Finally, since our study was 
conducted in patients with newly diagnosed T2DM, our findings are compatible 
with the hypothesis that the genetic clock of CVD in T2DM may start ticking long 
before the onset of overt diabetic hyperglycemia. 
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4.8 FIGURES and TABLES 
 
Table I. Clinical and metabolic features of the VNDS population. 
 
Variable ALL 
N (M/F) 597 (415/182) 
Age (years) 59 [52-66] 
BMI (Kg·m-2) 29.3 [26.5-32.8] 
Waist (cm) 100 [93-108] 
Smokers (%)* 47.9 [44.8-50.9] 
HbA1c DCCT (%) 6.7 [6.2-7.5] 
HbA1c IFCC (mmol/mol) 49.7 [44.3-58.5] 
Common carotid artery atherosclerosis 
(N=597)  
 absent (%)*  34.7 [31.8-37.6] 
 impaired IMT or stenosis <40% 59.8 [56.8-62.8] 
 stenosis ≥40% 5.5 [4.1-6.9] 
ECG ischemic abnormalities§ (N=489)  
 absent (%)* 70.6 [67.8-73.4] 
 possible 20.9 [18.4-23.4] 
 probable 2.2 [1.3-3.1] 
 definite 6.3 [4.8-7.8] 
Insulin Sensitivity (N=597)  
         M-clamp (µmol/min/m2 BSA) 607 [380-865] 
         Matsuda Index 3.0 [2.1-4.7] 
Beta-cell Function (N=595)  
         Derivative Control  
         (pmol/m2 BSA)·(mmol·L−1·min−1)−1 444 [68-938] 
         Proportional Control 
         (pmol·min−1·m−2 
BSA) 
ISR5.5 151 [110-191] 
ISR8 206 [149-282] 
ISR11 326 [228-473] 
ISR15 510 [331-764] 
ISR20 750 [461-1143] 
 
Data expressed as median and interquartile range [IQR]. *Percentage is given as point 
estimate at 95% confidence. §ECG abnormalities are classified according to the 
Minnesota code. BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic 
Blood Pressure; HbA1c DCCT, Diabetes Control and Complication Trial-Aligned 
Hemoglobin A1c; HbA1c IFCC, International Federation of Clinical Chemistry-Aligned 
Hemoglobin A1c; IMT, Intima-Media Thickness. ISRn, Insulin Secretion Rate at any 
given (n) mM of plasma glucose. 
  
 					
96 
 
  Table II. Properties of the 10 genetic variants included in the VNDS 
association analyses. 
Locus Chr SNP	 MAF*	 Alleles	
H-W	
Equlibrium		
Y/N,	(p)	Minor§/Other	
IRS1 2 rs4675095	 0.09	 A/T	 Y,	(0.66)	
IRS1 2 rs1801278	 0.07	 A/G	 Y,	(0.57)	
ENPP
1 6 rs858340	 0.27	 A/G	
Y,	(0.40)	
ENPP
1 6 rs6939185	 0.37	 A/G	
Y,	(0.84)	
ENPP
1 6 rs9493119	 0.06	 G/A	
Y,	(0.051)	
ENPP
1 6 rs4897549	 0.28	 A/G	
Y,	(0.51)	
TRIB3 20 rs6139007	 0.28	 G/A	 Y,	(0.11)	
TRIB3 20 rs7265169	 0.09	 A/C	 Y,	(0.87)	
TRIB3 20 rs6115830	 0.47	 A/G	 Y,	(0.17)	
TRIB3 20 rs6076472	 0.31	 C/A	 Y,	(0.15)	
 
* MAF, Minor Allele Frequency in the VNDS study population. § Minor allele (considered as 
effect allele, in bold) defined according to the MAF in our population. H-W, Hardy Weinberg 
equilibrium; Y, yes; N, no. 
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Table III. Effects of rs4897549-A (ENPP1), rs4675095-T (IRS1) and rs7265169-A 
(TRIB3) alleles on measured CVD risk traits in the VNDS study participants.  
A - Odds ratio of carotid atherosclerosis in carriers of rs4897549-A allele (ENPP1). B- 
Odds ratio of carotid atherosclerosis in carriers of rs4675095-T allele (IRS1). C- Odds 
ratio of abnormal ECG in carriers of rs7265169-A allele (TRIB3). D- Simultaneous, 
independent association of rs4897549-A (ENPP1) and rs4675095-T (IRS1) alleles with 
carotid atherosclerosis. ECG abnormalities were classified as suggestive for “probable” 
or “definite” coronary heart disease (CHD) according to the Minnesota code [14]. All 
analyses were adjusted for age, sex and smoking status. 
 
 
A. rs4897549-A (ENPP1) 
Phenotype adjusted OR 95% C.I. P-value 
Impaired CC-IMT and/or 
stenosis <40% 1.26 0.92 – 1.72 0.15 
Stenosis > 40% 2.64 1.40 – 4.96 0.003 
 0.01 (Poverall) 
 
B. rs4675095-T (IRS1) 
Phenotype adjusted OR 95% C.I. P-value 
Impaired CC-IMT and/or 
stenosis <40% 2.05 1.27 – 3.32 0.003 
Stenosis > 40% 2.69 0.86 – 8.47 0.09 
 0.009 
(Poverall) 
  C. rs7265169-A (TRIB3) 
Phenotype 
 adjusted OR 95% C.I. P-value 
  “Probable” CHD  1.79 1.05 – 3.04 0.033 
  “Definite” CHD 2.9 1.29 – 6.56 0.01 
 0.014 (Poverall) 
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D. rs4897549-A (ENPP1) rs4675095-T (IRS1) 
Phenotype adj OR 95% C.I. 
P-
value 
adj 
OR 95% C.I. 
P-
value 
Impaired CC-IMT 
and/or stenosis 
<40% 
1.23 0.89 – 1.69 0.21 2.08 1.28 – 3.39 0.003 
Stenosis > 40% 2.55 1.36 – 4.81 0.004 2.59 0.81 – 8.27 0.11 
 0.014 (Poverall) 
 0.009 (Poverall) 
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Figure 1 – Association between clamp-assessed insulin sensitivity and rs858340-G 
(ENPP1). 
The G allele of rs858340 (ENPP1) is significantly associated with impaired insulin 
sensitivity in patients with newly diagnosed type 2 diabetes (p=0.008, after correction for 
age, sex and BMI). Data are presented as median and interquartile range. BSA, body 
surface area. 
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Figure 2 – Relationships of intermediate cardiovascular disease traits and insulin 
resistance with genetic variants at insulin signalling pathway loci. 
The figure highlights the role of insulin resistance (IR, light grey set) as a well-
established predictor of cardiovascular disease (CVD, dark grey set). In this context, our 
study suggests that the common genetic variability of ENPP1 is associated with IR and 
intermediate CVD phenotypes, while TRIB3 is associated with ECG ischemic 
abnormalities and IRS1 with carotid atherosclerosis. 
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5.1 ABSTRACT 
 
English 
Background and Aims - Cardiovascular diseases (CVD) are a major cause of 
death and are often associated with type 2 diabetes (T2D). Genome-wide studies 
(GWAS) identified loci associated with T2D, CVD and traits leading to early 
death. We investigated whether these loci in aggregate carry a higher risk of all-
cause and CVD mortality in the FHS.  
Methods - We computed an unweighted genetic risk score (GRS) of 96 variants 
selected by effect-size within respective GWAS to represent the top 25% of 
GWAS variants for the following traits: T2D, coronary artery disease, myocardial 
infarction (MI), stroke, sudden cardiac death, heart rate, long QT-interval, heavy 
smoking and 15-years all-cause mortality. We used pooled logistic regressions 
with genetic-only (GRS adjusted for sex) and full CVD risk factors adjusted 
models (sex, age, smoking, prevalent non-fatal CVD) to test the association of 96-
GRS with all-cause and MI/stroke mortality in 3,426 FHS participants across 29 
years follow-up (p<0.025 (p=0.05/2) for significance).  
Results - Prevalence of non-fatal CVD, T2D and smoking was 7.5, 6.1 and 26.4% 
at baseline and 18.5, 15.9 and 13.2%, respectively, at the beginning of the last 
period considered. Cumulative incidence of fatal MI/stroke and all-cause 
mortality was 5.1 and 22.5%, respectively. The 96-GRS was associated with 
MI/stroke mortality in both genetic-only (OR[95%CI]: 1.04[1.0-1.1], p=0.006) 
and fully adjusted model (1.04[1-1.1], p=0.009). Association with all-cause 
mortality did not reach our statistical significance criteria (1.01[1-1.03], p=0.029, 
genetic-only; 1.02[1-1.03], p=0.034, fully adjusted).  
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Conclusions - An aggregate burden of 96 GWAS variants with the largest effect 
size on cardiometabolic traits is predictor of MI/stroke death in longitudinal 
analysis of a large population of European ancestry. Further studies need to 
specify the impact of cardiometabolic disease genetics on current mortality 
prediction models. 
 
 
Italian 
Premesse e Scopo - Il diabete tipo 2 (T2D) è una malattia complessa ad alta 
prevalenza e incidenza che riconosce fattori genetici e non-genetici quali 
determinanti causali. Le malattie cardiovascolari (CVD) sono una delle maggiori 
cause di morte e sono spesso associate a T2D. Studi di associazione genome-wide 
hanno identificato varianti genetiche comuni associate a T2D, CVD e fenotipi 
cardiometabolici intermedi. Questo studio verifica l’ipotesi se il rischio genetico 
per T2D e tratti di rischio cardiometabolico si associno ad aumentata mortalità 
nello studio Framingham. 
 
Metodi e Risultati - Popolazione: 3,426 soggetti arruolati nello studio FHS e 
seguiti con follow-up massimo di 29 anni. E’ stato calcolato un GRS96 composto 
da 96 tag-SNPs selezionati, in base al rispettivo effect-size, per essere 
rappresentativi del quartile più alto per ciascuno dei seguenti tratti all’interno dei 
rispettivi GWAS: T2D, malattie coronariche, infarto miocardico (MI), stroke, 
morte cardiaca improvvisa, frequenza cardiaca, QT-lungo, abitudine tabagica, 
mortalità per tutte le cause a 15 anni. Analisi: regressione logistica “pooled”. 
Modelli: M1=GRS+sex; M2: M1+età, fumo, storia personale di CVD non fatale. 
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Endpoints: (1) mortalità per tutte le cause; (2) mortalità per MI/stroke. 
Significatività: p<0.025 (=0.05/2). 
 
Conclusioni - La prevalenza di CVD non fatali, T2D e tabagismo era pari a 7.5, 
6.1 e 26.4% al baseline (Pool I) e 18.5, 15.9 e 13.2%, rispettivamente, all’inizio 
dell’ultimo periodo considerato (Pool IV). L’incidenza cumulativa di MI/stroke 
fatali e mortalità per tutte le cause era 5.1 e 22.5%, rispettivamente. Il GRS96 era 
associato a mortalità per MI/stroke sia nel modello M1 (OR [95%CI]: 1.04 [1-1.1], 
p=0.006), sia nel modello M2 (1.04 [1-1.1], p=0.009). L’associazione con 
mortalità per tutte le cause non raggiungeva la significatività statistica (1.01 [1.0-
1.03], p=0.029, modello M1; 1.02 [1.0-1.03], p=0.034, modello M2).  
  
 					
110 
5.2 INTRODUCTION 
 
Gauging how various diseases and injuries are affecting the living is a way to 
measure the effectiveness of a country’s health system and to better (re)direct 
human and economic resources to effectively improve the public health.  
Type 2 diabetes (T2D) and cardiovascular diseases (CVD) are well known to be 
clinically associated in adults [1, 2] and are becoming an increasing public health 
and economic scourge in US [3] and worldwide [4-6]. Moreover, cardiometabolic 
diseases are presently the major cause of death, according to a WHO 2013 report 
[7], and multiple large genome-wide association studies (GWAS) have thus far 
identified numerous loci associated with cardiometabolic diseases and conditions 
that often lead to early death. It can be reasonably hypothesized that if index SNPs 
at these loci are marking genes or regions with important functional significance 
for health, then the aggregate burden of these variants should be associated with 
an increased risk of mortality. 
 
This project sought to investigate in the FHS SHARe Study sample a “mortality” 
genetic risk score comprised of up to 96 candidate single nucleotide 
polymorphisms (SNPs) identified from published GWAS. The principle behind 
the selection of relevant SNPs was built upon a thorough literature review of 
currently available evidence (as of late 2014) from GWAS on mortality associated 
traits or phenotypes, including a spectrum of cardiometabolic diseases spanning 
from cardiovascular disease risk factors, particularly T2D, to overt cardiovascular 
diseases [8-17]. 
We hypothesized that a genetic risk score summed from up to 96 mortality 
phenotype-associated SNPs identified from published large scale GWAS would 
be associated with all-cause and cardiovascular disease mortality in the FHS 
mortality follow-up data.  
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This project was initiated with the expectation to provide orthogonal information 
to usual all-cause and CVD mortality risk prediction rules, which are commonly 
based on clinical measures and information. This approach would be of valuable 
practical utility to link the available genetic knowledge on cardiometabolic risk 
and all-cause mortality with the clinical tools currently in use to stratify the 
cardiometabolic risk and to manage disease care and prevention at the level of 
single individual and on larger population scale. 
 
 
5.3 METHODS 
 
Multiple GWAS have identified loci associated with diseases and conditions that 
often lead to early death. Our literature review identified about 96 SNPs 
potentially associated with mortality. To test this hypothesis we have used 
SHARe genotypes for 96 index SNPs from 96 loci reported in large-scale 
cardiometabolic disease / cardiovascular disease GWAS to be associated with 
myocardial infarction or coronary heart disease (CHD) death, stroke or stroke 
death, ECG-measured high heart rate or prolonged QRS interval or sudden 
cardiac death, T2D, heavy cigarette smoking behavior, or all-cause mortality. 
SNPs were selected by an exhaustive literature review of current GWAS and a 
subsequent assembly of a master list of about 96 top potentially mortality-related 
SNPs. The SNPs are shown in Table 1. 
For the 96 mortality SNPs, we have generated a genetic burden risk score by 
summing the presence of 0, 1 or 2 risk loci across the 96 SNPs of interest, where a 
higher score indicates a greater burden of potentially mortality-associated loci. 
The genetic risk score was un-weighted (simple allele counting). The genetic risk 
score was tested for association with mortality in the FHS SHARe mortality-
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linked follow-up data in linear additive genetic models. The primary analysis was 
focused on all-cause mortality and secondary analysis was focused on 
cardiovascular disease mortality. Other considerations explored in the analysis 
included testing mortality from participant entry to the study until death versus 
from the date of genotyping until death, to try and account for survival biases 
inherent in mid-life, mid-cohort study collection of genetic information.  Models 
were designed to control versus stratify by prevalent cardiovascular disease and 
T2D to account for confounding by diseases linked both to the genetic exposure 
and elevated risk for early mortality.  
 
 
Statistical analysis 
We used pooled logistic regressions with genetic-only (Model 1: GRS adjusted 
for sex) and full CVD risk factors adjusted models (Model 2: GRS adjusted for 
sex, age, smoking, prevalent CVD) to test the association of the 96-GRS with all-
cause and MI/stroke mortality in 3,426 FHS participants over a 29-years follow-
up period. Threshold for significance was declared at p<0.025 (p=0.05/2, the 
number of endpoints).  
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In summary: 
• Study design: longitudinal, population-based. 
• Study participants: 3,426 subjects of European Ancestry enrolled in the 
Framingham Heart Study 
• Exclusion criteria: none. 
• Exposure: We computed an un-weighted genetic risk score (GRS) of 96 
variants selected by effect-size within respective GWAS to represent the 
top 25% of GWAS variants for the traits listed in Table 1.  
• Endpoints: (1) All-cause Mortality; (2) Myocardial infarction/Stroke 
Mortality 
 
 
 
 
Composition of the genetic risk score* 
Phenotype SNP# PMID 
Type 2 Diabetes 36 22885922 
Coronary Artery Disease 31 23202125 
Smoking/cigarettes per day 7 20418890 
Myocardial Infarction 7 22397355 
Stroke 5 23041239 
Sudden Cardiac Death 4 23583979 
Heart Rate 3 23593153 
Long QT-Interval 3 19305408 
*More details are provided in Table 2 
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5.4 RESULTS 
 
Highlights (full descriptives are available in Table 2) 
 
Genetic Risk Score distribution at study entry 
 Pool 1 
(1983-1991) 
GRS96 (whole population) 88.2 (5.6) 
GRS96 (in people dead by stroke or MI) 89.9 (6.0) 
GRS96 (in people dead by all- causes) 88.8 (6.5) 
 
 
 
Cumulative incidence of deaths over 29-years of follow-up 
Stroke + MI (% of all population) 5.1 % 
All-cause (% of all population) 22.5 % 
 
 
The 96-GRS was significantly associated with Myocardial Infarction/stroke 
mortality  
 OR [95% C.I.] P-value 
Model 1 1.04 [1.0-1.1] 0.006 
Model 2 1.04 [1.0-1.1] 0.009 
 
 
 
Association with all-cause mortality did NOT reach statistical significance (p<0.025)  
 OR [95% C.I.] P-value 
Model 1 1.01[1-1.03] 0.029 
Model 2 1.02[1-1.03] 0.034 
 
-Model 1:  Mortality outcome (either ALL-cause or MI/stroke)= 96-GRS+Sex 
-Model 2: Mortality outcome = 96-GRS + sex, age, smoking, prevalent CVD (defined as defined as history of 
myocardial infarction, angina pectoris, and/or coronary insufficiency) 
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5.5 DISCUSSION 
Type 2 diabetes, prediabetic hyperglycemia and related CVD complications are 
becoming a dramatically increasing burden for the healthcare system in the U.S. 
[18]. The genetic knowledge in the field of these complex cardiometabolic 
diseases is expected to substantially contribute in the refinement of future 
healthcare strategies and to improve the clinical prediction tools currently 
available to assess diabetes risk development and related CVD complications 
and/or mortality. Large-scale genetic studies (GWAS) have successfully outlined 
the common variants genetic architecture of T2D and many other cardiometabolic 
diseases in people of European ancestry [17]. Some genetic insights also exist on 
the common allelic variation of genetic loci found to be associated with mortality-
related phenotypes or all-cause mortality [8-17]. 
Further population-based studies are still needed to specify how the allelic 
spectrum of cardiometabolic disease and mortality phenotype-associated SNPs 
can contribute to better define mortality prediction for population and 
personalized prevention strategies. Study of these questions in FHS SHARe 
permits analyses and interpretations in a large population sample followed-up 
over a time frame long enough to detect possible associations, if any, between 
genetics and mortality. 
The growing number of cardiometabolic disease risk loci (especially associated 
with type 2 diabetes) and mortality phenotype-associated SNPs discovered since 
the beginning of GWAS era might be a valuable tool requiring further testing to 
verify the ability to predict mortality. The availability of the FHS SHARe 
mortality-linked follow-up data affords the unique opportunity to test hypotheses 
about the ultimate population impact of modern genetic discoveries and variation 
on the cardiometabolic risk and all-cause mortality in the US population. 
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In this exercise we successfully tested the association of MI/stroke mortality with 
a genetic risk score summed from up to 96 mortality phenotype-associated SNPs 
identified from published large scale GWAS for association with mortality in the 
FHS SHARe mortality follow-up data. 
Although our results are far from being conclusive, as they need to be replicated 
in independent cohorts, the encouraging results obtained in this pilot study with a 
restricted set of around 100 SNPs encourage further studies exploring the impact 
of the entire spectrum of cardiometabolic disease genetic variants on current 
mortality prediction models, in order to properly represent the most updated 
GWAS landscape on cardiometabolic risk traits or phenotypes.  
As stated above, T2D and CVD are common diseases that often clinically occur 
together. They carry a high risk of death (either all-cause or due to MI/stroke) and 
share common risk factors. Both T2D and CVD have a strong genetic background 
and it is therefore possible that they lead to early (CVD) death through common 
genetic pathways. Recent evidences have shown that the genetic predisposition to 
T2D, as modeled by a composite genetic risk score, is associated with increased 
all-cause mortality risk (Leong A et al., 2016) and with non-fatal and fatal CVD 
(Borglykke A et al., 2012). It is however currently unknown whether the higher 
all-cause and MI/stroke death rates carried by the genetic burden of T2D risk 
occur independently of the individual genetic predisposition to CVD. It might also 
be possible that the genetic risk for T2D represents a permissive (genetic) 
environment that paves the way to the overt manifestation of CVD genetic risk. 
All these questions, therefore, require specific study designs; as such, starting 
from the pilot analyses of the project herein presented, future studies are 
advocated to untangle, at a genetic level, the common soil underlying the strong 
clinical link existing between T2D and CVD.   
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5.6 TABLES 
 
Table 1 – 96 SNPs included in the “mortality” genetic risk score 
# Nearest gene SNP Chr Risk allele Disease/Trait PMID # 
1. TCF7L2 rs7903146 10 T T2D 22885922 
2. CDKN2A/B rs10811661 9 T T2D 22885922 
3. CDKAL1 rs7756992 6 G T2D 22885922 
4. SLC30A8 rs3802177 8 G T2D 22885922 
5. THADA rs10203174 2 C T2D 22885922 
6. FTO rs9936385 16 C T2D 22885922 
7. IGF2BP2 rs4402960 3 T T2D 22885922 
8. PPARG rs1801282 3 C T2D 22885922 
9. HMGA2 rs2261181 12 T T2D 22885922 
10. HHEX/IDE rs1111875 10 C T2D 22885922 
11. ADCY5 rs11717195 3 T T2D 22885922 
12. JAZF1 rs849135 7 G T2D 22885922 
13. ARAP1 (CENTD2) rs1552224 11 A T2D 22885922 
14. DGKB rs17168486 7 T T2D 22885922 
15. HNF1B (TCF2) rs11651052 17 A T2D 22885922 
16. MTNR1B rs10830963 11 G T2D 22885922 
17. ZBED3 rs6878122 5 G T2D 22885922 
18. IRS1 rs2943640 2 C T2D 22885922 
19. WFS1 rs4458523 4 G T2D 22885922 
20. KHLDC5 rs10842994 12 C T2D 22885922 
21. ANK1 rs516946 8 C T2D 22885922 
22. KCNQ1 rs163184 11 G T2D 22885922 
23. ADAMTS9 rs6795735 3 C T2D 22885922 
24. ZMIZ1 rs12571751 10 A T2D 22885922 
25. CILP2 rs10401969 19 C T2D 22885922 
26. BCAR1 rs7202877 16 T T2D 22885922 
27. UBE2E2 rs1496653 3 A T2D 22885922 
28. HNF1A (TCF1) rs12427353 12 G T2D 22885922 
29. ANKRD55 rs459193 5 G T2D 22885922 
30. CCND2 rs11063069 12 G T2D 22885922 
31. MC4R rs12970134 18 A T2D 22885922 
32. HMG20A rs7177055 15 A T2D 22885922 
33. PRC1 rs12899811 15 G T2D 22885922 
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34. SPRY2 rs1359790 13 G T2D 22885922 
35. NOTCH2 rs10923931 1 T T2D 22885922 
36. GCK rs4607517 7 A T2D 22885922 
37. ZNF365 rs2077316 10 C Sudden Cardiac Death (SCD) 23593153 
38. BAZ2B rs4665058 2 A Sudden Cardiac Death (SCD) 21738491 
39. RAB3GAP1 rs6730157 2 G Sudden Cardiac Death (SCD) 23593153 
40. HDAC9 rs2107595 7p21.1 A STROKE (ischemic) 23041239 
41. ZFHX3 rs879324 16q22.3 A STROKE (ischemic) 23041239 
42. Intergenic rs13407662 2p16.2 T STROKE (ischemic) 23041239 
43. NINJ2 rs12425791 12p13.33 A STROKE (ischemic) 19369658 
44. PITX2 rs6843082 4q25 G STROKE (ischemic) 23041239 
45. BDNF rs6265 11p14.1 C Smoking initiation 20418890 
46. DBH rs3025343 9q34.2 G Smoking cessation 20418890 
47. CDKN2BAS1 rs3217992 9p21 A Coronary artery disease 23202125 
48. CDKN2BAS1 rs1333049 9p21 C Coronary artery disease 23202125 
49. KCNE2 rs9982601 21q22.11 T Coronary artery disease 23202125 
50. SORT1 rs602633 1 C Coronary artery disease 23202125 
51. WDR12 rs6725887 2 C Coronary artery disease 23202125 
52. ApoE-ApoC1 rs2075650 19 G Coronary artery disease 23202125 
53. PPAP2B rs17114036 1p32.2 A Coronary artery disease 23202125 
54. LDLR rs1122608 19p13.2 G Coronary artery disease 23202125 
55. PHACTR1 rs9369640 6p24.1 C Coronary artery disease 23202125 
56. ZC3HC1 rs11556924 7 C Coronary artery disease 23202125 
57. COL4A1, COL4A2 rs9515203 13 T Coronary artery disease 23202125 
58. ADAMTS7 rs7173743 5 T Coronary artery disease 23202125 
59. ABO rs579459 9 C Coronary artery disease 23202125 
60. PDGFD rs974819 11 A Coronary artery disease 23202125 
61. SH2B3 rs3184504 12 T Coronary artery disease 23202125 
62. TCF21 rs12190287 6 C Coronary artery disease 23202125 
63. HHIPL1 rs2895811 14q32 C Coronary artery disease 23202125 
64. KIAA1462 rs2505083 10 C Coronary artery disease 23202125 
65. PCSK9 rs11206510 1 T Coronary artery disease 23202125 
66. RASD1, SMCR3, PEMT rs12936587 17p11.2 G Coronary artery disease 23202125 
67. SLC22A3-LPAL2-LPA rs2048327 6 G Coronary artery disease 23202125 
68. SLC22A4-SLC22A5 rs273909 5 C Coronary artery disease 23202125 
69. ZNF259, APOA5, APOA1 rs9326246 11 C Coronary artery disease 23202125 
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70. APOB rs515135 2 G Coronary artery disease 23202125 
71. CXCL12 rs501120 10q11 A Coronary artery disease 23202125 
72. MRAS rs9818870 3 T Coronary artery disease 23202125 
73. ABCG5-ABCG8 rs6544713 2 T Coronary artery disease 23202125 
74. GUCY1A3 rs7692387 4 G Coronary artery disease 23202125 
75. KCNK5 rs10947789 6 T Coronary artery disease 23202125 
76. PLG rs4252120 6 T Coronary artery disease 23202125 
77. MIA3 rs17464857 1q41 T Coronary artery disease 23202125 
78. CHRNA3 rs1051730 15q25.1 G Cigarettes per day (CPD) 20418890 
79. LOC100188947 rs1329650 10q23.32 T Cigarettes per day (CPD) 20418890 
80. CYP2A6,EGLN2 rs3733829 19q13.2 G Cigarettes per day (CPD) 20418890 
81. CYP2A6,RAB4D rs4105144 19q13.2 C Cigarettes per day (CPD) 20418888 
82. CHRNB3,CHRNA6 rs6474412 8p11.21 T Cigarettes per day (CPD) 20418888 
83. WRN rs6997892 8 G 15-year all-cause mortality 22397355 
84. IGF1R rs2684766 15 T 15-year all-cause mortality 22397355 
85. TRIM32 rs10817931 9 A 15-year all-cause mortality 22397355 
86. MAT2B rs1421783 5 C 15-year all-cause mortality 22397355 
87. IGF1R rs11630259 15 T 15-year all-cause mortality 22397355 
88. APOE rs7412 19 C 15-year all-cause mortality 22397355 
89. APOE rs429358 19 C 15-year all-cause mortality 22397355 
90. NOS1AP rs12143842 1q T QT-interval 19305408 
91. 
CNOT1 ,GINS3, 
NDRG4, 
SLC38A7, GOT2 
rs37062 16q G QT-interval 19305408 
92. SLC35F1, PLN, ASF1A rs11756438 6q A QT-interval 19305408 
93. CCDC141 rs17362588 2 A Heart Rate 23583979 
94. GJA1 rs1015451 6 C Heart Rate 23583979 
95. CD46 rs11118555 1 A Heart Rate 23583979 
96. MYH6 rs365990 14 G Heart Rate 23583979 
   
 
Table 1 – Baseline anthropometric and clinical characteristics of Framingham Offspring Cohort participants in 4 pooled study examination. 
 
Pool 1 
(1983-1991)  
Pool 2  
(1991-1998) 
Pool 3  
(1998-2005) 
Pool 4  
(2005-2011) 
 
 
 
 
 
N 
3,426 
3,337 
3,209  
2,723  
N (%) “Healthy” (i.e., non-CVD and subjects not taking meds for DM
/hypertension/lipids) 
2,716 (79.3) 
2,314 (69.2) 
1,709 (53.3) 
936 (34.4) 
N (males, %) All 
1,617 (47.2) 
1,511 (45.2) 
1,480 (46.1) 
1,227 (45.1) 
Age, years 
48.0 (9.9) 
54.6 (9.8) 
61.3 (9.6) 
66.8 (9.2) 
BM
I, Kg/m
-2 
26.3 (4.7) 
27.4 (4.9) 
28.2 (5.3) 
28.2 (5.3) 
Systolic blood pressure, mmHg 
123.3 (16.9) 
125.8 (18.6) 
127.0 (18.7) 
128.5 (17.3) 
Lipids, mg/dL 
 
 
 
 
 
Total Cholesterol 
210.2 (41.0) 
205.0 (37.1) 
200.3 (36.7) 
185.9 (37.3) 
 
LDL-C 
133.4 (36.2) 
126.6 (33.1) 
119.8 (32.8) 
105.2 (31.2) 
 
HDL-C 
51.3 (14.8) 
50.11 (15.1) 
53.8 (17.0) 
57.4 (18.1) 
 
Triglycerides 
120.5 (115.2) 
147.6 (115.7) 
137.2 (89.6) 
118.1 (69.5) 
Lipid lowering medication, N (%) 
34 (1.0) 
232 (6.9) 
676 (21.1) 
1,1,51 (42.3) 
Diabetics, N (%) 
209 (6.1) 
377 (11.3) 
421 (13.1) 
433 (15.9) 
Diabetes medication, N (% of diabetics) 
54 (25.8) 
104 (27.6) 
221 (52.5) 
253 (58.4) 
Fasting plasma glucose, mg/dL 
94.0 (20.4) 
100.5 (27.6) 
104.1 (26.5) 
106.6 (23.6) 
Hypertension, N (%)  
1,012 (29.5) 
1,064 (31.8) 
1,468 (45.8) 
1,594 (58.6) 
Antihypertensive medication, N (% of hypertensive subjects) 
519 (51.3) 
578 (54.3) 
1,090 (74.3) 
1,354 (84.9) 
Smoking status, N (%) 
 
 
 
 
 
Current smoker 
903 (26.4) 
643 (19.2) 
507 (15.8) 
359 (13.2) 
 
Previous smoker 
1,387 (40.5) 
1,583 (47.4) 
1,627 (50.7) 
1,417 (52.0) 
 
Never smoker 
1,136 (33.2) 
1,117 (33.4) 
1,075 (33.5) 
947 (34.8) 
Personal CVD* history, N (%)  
257 (7.5) 
367 (11.0) 
379 (11.8) 
505 (18.5) 
GRS
96  (whole population) 
88.2 (5.6) 
88.2 (5.6) 
88.1 (5.6) 
88.1 (5.6) 
GRS
96  (in people dead by stroke or M
I) 
89.9 (6.0) 
90.8 (6.0) 
89.0 (5.6) 
89.4 (6.1) 
GRS
96  (in people dead by all- causes) 
88.8 (6.5) 
90.1 (6.1) 
88.2 (5.7) 
88.4 (5.5) 
CVD events (fatal + non-fatal) **, N (%) 
278 (8.1) 
386 (11.5) 
459 (14.3) 
560 (20.6) 
Deaths, N (%) 
 
 
 
 
 
Stroke + myocardial infarction (% of all population) 
21 (0.6) 
18 (0.5) 
80 (2.5) 
55 (2.0) 
 
Stroke + myocardial infarction in Healthy, N (% of healthy) 
6 (0.2) 
10 (0.4) 
17 (1.0) 
4 (0.4) 
 
Cancer (% of all deaths) 
34 (39.5) 
55 (48.3) 
107 (33.3) 
95 (38.2) 
 
Non-cancer deaths (% of all population) 
52 (1.5) 
60 (1.8) 
214 (6.7) 
154 (5.7) 
 
All-cause (% of all population) 
86 (2.5) 
115 (3.5) 
321 (10.0) 
249 (9.1) 
*CVD, cardiovascular disease, defined as history of myocardial infarction, angina pectoris, coronary insufficiency. AF, atrial fibrillation. LVH-ECG, left ventricular hypertrophy as evaluated 
by electrocardiogram. GRS, genetic risk score. 
**CVD events (fatal + non-fatal), composite endpoint comprising fatal myocardial infarction, fatal stroke,	non-fatal M
I, non-fatal stroke, coronary artery disease (angina pectoris, coronary 
insufficiency). 
Data expressed as mean ± standard deviation (SD) unless otherwise indicated. 
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Experimental design 
A multivariable linear regression model with random effects to account for family 
relatedness was applied, where appropriate, to test the association of subclinical 
atherosclerosis (SCA) measures with an additive genetic risk score (GRS62) 
comprised of 62 single nucleotide polymorphisms (SNPs) known to be linked 
with type 2 diabetes (T2D) risk (Appendix Table 1) [1]. Many of them are 
associated with either beta-cell function or insulin resistance (IR) physiology. 
Therefore, as described in [2], we used prior genetic and physiologic evidence [1, 
3-6] to define a sub-GRS comprised of 20 T2D SNPs mainly associated with 
beta-cell function (GRSβ) and a sub-GRS comprised of 10 T2D SNPs associated 
with peripheral insulin resistance (GRSIR), with each locus weighted in European 
Americans by the same effect size as in the GRS62. 
For each SCA trait a genetic-only model (adjusted for sex) and a full 
atherosclerosis risk factors adjusted model (Appendix Table 2) were applied. 
Clinical and anthropometric characteristics of study cohorts are shown in 
Appendix Table 3 and Appendix Table 4. The GRSβ and GRSIR were tested only 
in FHS and CARDIA study samples (Appendix Table 5-6).  
Many of the 62 tag-SNPs associated with T2D (Appendix Table 1) are also 
known to be associated with SCA risk factors/confounders. Genome.gov 
(http://www.genome.gov/), a catalog of published GWAS, and PheGenI 
(http://www.ncbi.nlm.nih.gov/gap/phegeni), a phenotype-oriented resource 
housed at the National Center for Biotechnology Information, were interrogated. 
Risk factors listed in the catalogs as being associated with one or more of the 
known 62 T2D loci were included, among others, in the full model (BMI, waist 
circumference, systolic blood pressure, fasting insulin, fasting glucose, 
triglycerides, HDL-cholesterol and LDL-cholesterol). Therefore, the basic model 
could be described as “purely” genetic, as it tested the association of a T2D GRS 
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alone with SCA traits, after adjustment for sex, while the full model accounted for 
the overall spectrum of confounders, mediators and/or risk factors for SCA 
available in the dataset, by adjusting for a comprehensive list of atherosclerosis 
risk factors. 
 
Genotyping 
MESA: Caucasian, Hispanic, and Chinese American participants were genotyped 
on the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, 
CA, USA) at the Affymetrix Research Services Lab. 6,880 samples passed initial 
genotyping QC. African American samples were genotyped at the Broad Institute 
of Harvard and MIT as part of the CARe project [7]. Affymetrix performed wet 
lab hybridization assay, and plate-based genotype calling using Birdseed v2. 
Sample QC was based on call rates and contrast QC (cQC) statistics. Broad 
performed similar QC for CARe sample. Additional sample and SNP QC were 
carried out at University of Virginia, including sample call rate, sample cQC, and 
sample heterozygosity by ethnicity at the sample level; outlier plates checking by 
call rate, median cQC or heterozygosity at plate level.  Four samples were 
removed due to low call rate (<95%). Cryptic sample duplicates or unresolved 
cryptic duplicates were dropped. Unresolved gender mismatches were also 
dropped. At the SNP level, we excluded monomorphic SNPs across all samples; 
SNPs with missing rate was > 5% or observed heterozygosity > 53% were also 
excluded. Additional genotypes were imputed to the 1000 Genomes Phase I 
integrated variant set (NCBI build 37 / hg19) separately in each ethnic group 
using the program IMPUTEv2. We used data freezes from 23 Nov 2010 (low-
coverage whole-genome) and 21st May 2011 (high-coverage exome), phased 
haplotypes released March 2012 (v3), and phased haplotypes for 1,092 
individuals and over 39 million variants. All imputed and genotyped SNPs were 
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aligned to the '+' strand of the human genome reference sequence (NCBI Build 
37). The Affymetrix annotation file "GenomeWideSNP_6.na31.annot.csv" was 
used for all matching of probe set IDs with RS IDs. 
GENOA: GENOA Study participants were genotyped on the Affymetrix 
Genome-Wide Human SNP Array 6.0 (Affymetrix, 2007) or the Illumina Human 
1M-Duo BeadChip (Illumina, 2010) at the Mayo Clinic, Rochester, MN. African 
American sibships for the GENOA study were identified using hypertensive 
participants from the Atherosclerosis Risk in Communities Study (ARIC) as 
probands. Genotypes were obtained for 92 additional GENOA participants who 
were also in the ARIC Study and who could not be genotyped on either platform 
using the GENOA blood sample. Genotyping for the ARIC study was done at the 
Broad Institute on the Affymetrix 6.0 platform. For all genotyping platforms used, 
samples and SNPs with a call rate <95% were removed. Samples demonstrating 
sex mismatch, duplicate samples, and samples with low identity-by-state with all 
other samples were also removed. Imputation was performed with the single-step 
approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16 [8]. The 
reference panel was composed of the HapMap phased haplotypes (release 22). 
Imputation was performed separately for participants genotyped on the 
Affymetrix 6.0 as part of the GENOA study, participants genotyped on the 
Illumina Human 1M-Duo BeadChip, and participants genotyped on the 
Affymetrix 6.0 as part of the ARIC Study. Since only a small number of directly 
genotyped SNPs overlap on the Affymetrix and Illumina platforms, imputed 
dosages were used for all. 
In GENOA African Americans the GRS was limited to 55 SNPs due to poor 
imputation quality for 7 SNPs. FHS and CARDIA genotyping and imputation 
strategy have been previously detailed elsewhere[2, 7, 9, 10]. 
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Appendix Table 1 - 62 independent loci and relative tag-SNPs associated with Type 2 
Diabetes from DIAGRAMv3 [1] 
 
 
 
Chr SNP-risk allele Locus OR Chr SNP-risk allele Locus OR 
1 rs2075423-G PROX1 or PPP2R5A 1.07 9 rs10758593-A GLIS3 1.06 
1 rs10923931-T NOTCH2 1.08 9 rs17791513-A TLE4 1.12 
2 rs10203174-C THADA 1.14 9 rs2796441-G TLE1 1.07 
2 rs243088-T BCL11A 1.07 9 rs16927668-T PTPRD 1.04 
2 rs13389219-C GRB14 1.07 10 rs11257655-T CDC123/CAMK1D 1.07 
2 rs2943640-C IRS1 1.10 10 rs7903146-T TCF7L2 1.39 
2 rs7569522-A RBMS1 1.05 10 rs1111875-C HHEX/IDE 1.11 
2 rs780094-C GCKR 1.06 10 rs12571751-A ZMIZ1 or PPIF 1.08 
3 rs11717195-T ADCY5 1.11 10 rs12242953-G VPS26A 1.07 
3 rs1496653-A UBE2E2 1.09 11 rs10830963-G MTNR1B 1.10 
3 rs4402960-T IGF2BP2 1.13 11 rs1552224-A ARAP1 (CENTD2) 1.11 
3 rs1801282-C PPARG 1.13 11 rs163184-G KCNQ1 1.09 
3 rs6795735-C ADAMTS9 1.08 11 rs5215-C KCNJ11 1.07 
3 rs12497268-G PSMD6 1.03 11 rs2334499-T DUSP8 or HCCA2 (YY1AP1) 1.04 
3 rs17301514-A ST64GAL1 1.05 12 rs7955901-C TSPAN8/LGR5 1.07 
4 rs6819243-T MAEA 1.07 12 rs12427353-G HNF1A (TCF1) 1.08 
4 rs4458523-G WFS1 1.10 12 rs2261181-T HMGA2 1.13 
5 rs6878122-G ZBED3 or PDE8B 1.10 12 rs10842994-C KLHDC5 or PPFIBP1 1.10 
5 rs459193-G ANKRD55 1.08 13 rs1359790-G SPRY2 1.08 
6 rs7756992-G CDKAL1 1.17 15 rs4502156-T C2CD4A or VPS13C 1.06 
6 rs3734621-C KCNK16 1.07 15 rs11634397-G ZFAND6 1.05 
6 rs4299828-A ZFAND3 1.04 15 rs12899811-G PRC1 1.08 
7 rs17168486-T DGKB 1.11 15 rs2007084-G AP3S2 1.02 
7 rs10278336-A GCK  1.07 15 rs7177055-A HMG20A 1.08 
7 rs849135-G JAZF1 1.11 16 rs9936385-C FTO 1.13 
7 rs17867832-T GCC1 or PAX-4 1.09 16 rs7202877-T BCAR1 1.12 
7 rs13233731-G KLF14 1.05 17 rs2447090-A SRR 1.04 
8 rs3802177-G SLC30A8 1.14 18 rs12970134-A MC4R 1.08 
8 rs7845219-T TP53INP1 1.06 19 rs10401969-C CILP2 1.13 
8 rs516946-C ANK1 1.09 19 rs8182584-T PEPD 1.04 
9 rs10811661-T CDKN2A/B 1.18 20 rs4812829-A HNF4A 1.06 
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Appendix Table 2 – Outline of models applied in the association analysis of Genetic 
Risk Scores (GRS) with subclinical atherosclerosis traits, plus covariates. 
 
BASIC MODEL 
 
GRS, sex 
 
 
FULL MODEL GRS, sex 
 
Age 
BMI 
Waist circumference 
Systolic blood pressure (SBP)* 
 
Fasting insulin 
Fasting glucose 
Triglycerides 
HDL-Cholesterol 
LDL-Cholesterol 
 
Family history of T2D 
Family history of CVD 
 
Smoking status 
Physical activity 
 
Diabetes medication 
Hypertension medication 
Lipid-lowering medication 
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A
ppendix T
able 3 – Subclinical atherosclerosis m
easures, anthropom
etric and clinical characteristics in FH
S and C
A
R
D
IA
 cohorts. 
 
 
 
 
FH
S 
C
A
R
D
IA
 
 
 
 
 
 
 
Exam
 6 
Exam
 7 
Exam
 year 20 
Exam
 year 25 
 
 
 
 
 
Ethnicity 
E
uropean A
m
ericans 
A
frican A
m
ericans 
E
uropean A
m
ericans 
A
frican A
m
ericans 
E
uropean A
m
ericans 
N
 (m
ale %
) 
2459 (44.8%
) 
1111 (44.8%
) 
816 (38.6%
) 
1635 (45.9 %
) 
811 (38.8%
) 
1621 (45.9 %
) 
A
ge (yr) 
57.9 ± 9.6 
58.9 ± 8.9 
44.4 ± 3.8 
45.5 ± 3.3 
49.4 ± 3.8 
50.6 ± 3.3 
B
M
I (kg/m
2) 
27.6 ± 4.9 
28.1 ± 4.9 
31.7 ± 7.6 
27.9 ± 6.7 
32.2 ± 7.8 
28.2 ± 6.2 
W
aist circum
ference (cm
) 
96.5 ± 12.7 
96.5 ± 12.7 
94.7 ± 15.7 
89.8 ± 15.1 
97.1 ± 15.8 
91.6 ± 15.6 
Systolic blood pressure (m
m
H
g) 
127.1 ± 18.3 
124.9 ± 17.7 
119.1 ± 15.5 
112.2 ± 12.5 
122.2 ± 14.5 
114.5 ± 13.7 
Fasting glucose (m
g/dL) 
101.3 ± 22.9 
99.9 ± 18.2 
102.3 ± 30.2 
97.8 ± 21.2 
102.1 ± 34.6 
96.7 ± 20.4 
Fasting insulin (pm
ol/L) 
- 
14.3 ± 8.6 
17.1 ± 12.2 
13.5 ± 9.1 
13.39 ± 14.1 
9.6 ± 7.3 
Triglycerides (m
g/dL) 
136.1 ± 88.2 
132.6 ± 86.5 
96.4 ± 58.4 
116.9 ± 82.4 
101.4 ± 67.1 
120.0 ± 86.3 
H
D
L-cholesterol (m
g/dL) 
51.9 ± 16.1 
53.9 ± 15.9 
54.1 ± 16.3 
54.4 ± 17.2 
57.7 ± 17.3 
58.7 ± 18.5 
LD
L-cholesterol (m
g/dL) 
127.4 ± 32.9 
121.4 ± 31.3 
110.4 ± 33.6 
110.3 ± 30.5 
109.2 ± 33.9 
113.4 ± 30.9 
Parental history of diabetes (%
) 
19.8 
19.8 
17.9 
9.5 
17.6 
9.4 
Parental history of C
V
D
 (%
) 
43.2 
41.9 
39.8 
41.3 
39.9 
41.2 
D
iabetes (%
) 
7.1 
6.3 
10.9 
3.4 
13.3 
6.5 
Sm
okers (never/form
er/current - %
) 
35.8/48.9/15.2
* 
39.5/50.7/9.8
* 
59.9/40.1
** 
46.1/53.9
** 
62.2/37.9
** 
50.7/49.3
** 
Physical activity  
- 
- 
287.5±285.4
§ 
370.3±260.8
§ 
264.4±257.5
§ 
388.0±280.9
§ 
G
enetic R
isk Score 
66.7 ± 5.3 
66.7 ± 5.2 
69.2 ± 4.5 
66.4 ± 5.2 
69.2 ± 4.5 
66.4 ± 5.2 
 
 
 
 
 
C
om
orbidity status 
 
 
 
 
 
 
 
 
 
D
iabetes m
edication (%
) 
3.3 
2.9 
7.9 
3.4 
10.7 
4.6 
H
ypertension m
edication (%
) 
23.4 
24.8 
23.1 
10.2 
41.8 
31.8 
Lipid-low
ering m
edication (%
) 
9.8 
13.9 
- 
- 
- 
- 
 
 
 
 
 
Subclinical atherosclerosis traits 
 
 
 
 
 
 
 
 
 
A
A
C
S (A
gatston unit) 
- 
1458.6 ± 2332.3 
- 
- 
- 
- 
C
A
C
S (A
gatston unit) 
- 
229.8 ± 550.8 
- 
- 
31.7 ± 154.6 (n=586) 
49.2 ± 252.1 (n=1267) 
C
C
A
-IM
T (m
m
)  
0.5 ± 0.4 (n=2340) 
- 
0.7 ± 0.1 (n=617) 
0.7 ± 0.1 (n=1379) 
- 
- 
IC
A
-IM
T (m
m
)  
0.8 ± 1.9 (n=2035) 
- 
0.6 ± 0.2 (n=562) 
0.6 ± 0.2 (n=1332) 
- 
- 
A
B
I 
1.1 ± 0.1 (n=2822) 
- 
- 
- 
- 
 
 
 
 
 
 D
ata expressed as m
ean±standard deviation, if not otherw
ise indicated. A
A
C
S, abdom
inal aorta calcium
 score; C
A
C
S, coronary artery calcium
 score; C
C
A
, com
m
on carotid artery; IC
A
, internal 
carotid artery; IM
T, intim
a-m
edia thickness; A
B
I, ankle-brachial index. *Sm
oking status categorized as never/form
er/current in FH
S. **Sm
oking status categorized as never/ever in C
A
R
D
IA
. §Physical 
activity is expressed as Total Intensity Score, according to the C
A
R
D
IA
 Physical A
ctivity H
istory Q
uestionnaire (Pereira M
A
 et al.; PM
ID
: 9243481).  
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A
ppendix T
able 4 – Subclinical atherosclerosis m
easures, anthropom
etric and clinical characteristics in M
E
SA
 and G
E
N
O
A
 cohorts. 
 
 
 
 
M
E
SA
 
G
E
N
O
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethnicity 
E
uropean A
m
ericans 
A
sian A
m
ericans 
A
frican A
m
ericans 
H
ispanic A
m
ericans 
E
uropean A
m
ericans 
A
frican A
m
ericans §§ 
N
 (m
ale %
) 
2526 (47.7%
) 
773 (49.2%
) 
1611 (46.1%
) 
1446 (48.3%
) 
969 (40.9%
) 
535 (25.8%
) 
A
ge (yr) 
62.7 ± 10.2 
62.4 ± 10.4 
62.3 ± 10.1 
61.4 ± 10.3 
58.9 ± 9.5 
68.5 ± 7.7 
B
M
I (kg/m
2) 
27.7 ± 5.1 
23.9 ± 3.3 
30.2 ± 5.9 
29.5 ± 5.2 
30.7 ± 6.3 
32.7 ± 7.2 
W
aist circum
ference (cm
) 
97.9 ± 14.5 
87.1 ± 9.8 
101.3 ± 14.7 
100.7 ± 13.1 
100.3 ± 16.2 
101.1 ± 15.4 
Systolic blood pressure (m
m
H
g) 
123.5 ± 20.5 
124.6 ± 21.7 
131.8 ± 21.8 
126.8 ± 21.9 
131.4 ± 16.8 
137.5 ± 21.0 
Fasting glucose (m
g/dL) 
91.3 ± 21.6 
99.2 ± 28.6 
100.3 ± 32.7 
103.9 ± 39.4 
104.6 ± 24.5 
111.6 ± 37.7 
Fasting insulin (pm
ol/L) 
9.1 ± 5.6 
9.6 ± 12.5 
11.5 ± 27.5 
11.8 ± 15.7 
54.2 ± 40.3 
80.6 ± 87.5 
Triglycerides (m
g/dL) 
133 ± 90.1 
143.1 ± 85.7 
105.2 ± 70.5 
158.4 ± 101.8 
159.0 ± 96.9 
101.0 ± 63.3 
H
D
L-cholesterol (m
g/dL) 
52.4 ± 15.8 
49.3 ± 12.4 
52.3 ± 15.2 
47.5 ± 13.1 
52.4 ± 15.6 
57.1 ± 16.5 
LD
L-cholesterol (m
g/dL) 
117.1 ± 30.3 
115.1 ± 28.8 
116.7 ± 33.3 
119.9 ± 32.9 
122.7 ± 32.1 
114.6 ± 35.3 
Parental history of diabetes (%
) 
- 
- 
- 
- 
29.4 
40.9 
Parental history of C
V
D
 (%
) 
44.6/33.2/2.8
†  
14.5/23.3/1.2
† 
31.9/31/7
† 
31.2/23.8/3.2
† 
57.5
††  
56.1
†† 
D
iabetes (%
) 
5.9 
13.5 
17.4 
17.8 
13.5 
35.5 
Sm
okers (never/form
er/current - %
) 
33.1/66.9 
69.6/30.4 
26.6/73.4 
40.7/59.3 
52.5/37.3/10.2 
 60.4/31.4/8.2 
R
egular physical activity (daily hours) 
12.8 ± 4.9 
9.9 ± 4.4 
14.4 ± 7.1 
11.6 ± 5.9 
3.7 ± 2.5
§ 
1.0 ± 1.8
§ 
G
enetic R
isk Score 
63.9 ± 4.7 
61.5 ± 4.2 
56.5 ± 4.7 
62.7 ± 4.8 
64.2 ± 4.9 
57.0 ± 3.9 
 
 
 
 
 
 
 
C
om
orbidity status 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
iabetes m
edication (%
) 
4.6 
9.2 
13.6 
15.8 
8.9 
32.0 
H
ypertension m
edication (%
) 
33.3 
29.1 
50.3 
32.9 
68.4 
80.8 
Lipid-low
ering m
edication (%
) 
18.3 
14.1 
15.8 
13.3 
27.0 
40.9 
 
 
 
 
 
 
 
Subclinical atherosclerosis traits 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
A
C
S (A
gatston unit) 
1668.4 ± 2581.4 (n=760) 
1044.7 ± 2015.4 (n=247) 
887.2 ± 1737.7 (n=343) 
1044.6 ± 1898.4 (n=496) 
- 
- 
C
A
C
S (A
gatston unit) 
338.6 ± 577.2 (n=1433) 
205.8 ± 374.3 (n=392) 
294.0 ± 582.8 (n=714) 
281.4 ± 567.2 (n=659) 
201.6 ± 467.2 
236.3 ± 583.0 
C
C
A
-IM
T (m
m
)  
0.9 ± 0.2 (n=2501) 
0.8 ± 0.2 (n=770) 
0.9 ± 0.2 (n=1573) 
0.9 ± 0.2 (n=1431) 
- 
- 
IC
A
-IM
T (m
m
)  
1.1 ± 0.6 (n=2475) 
0.9 ± 0.5 (n=766) 
1.1 ± 0.6 (n=1547) 
1.0 ± 0.6 (n=1399) 
- 
- 
A
B
I 
1.1 ± 0.1 (n=2494) 
1.1 ± 0.1 (n=768) 
1.1 ± 0.1 (n=1432) 
1.3 ± 0.1 (n=1430) 
- 
- 
 
 
 
 
 
 
 
 D
ata expressed as m
ean±standard error, if not otherw
ise indicated. A
A
C
S, abdom
inal aorta calcium
 score; C
A
C
S, coronary artery calcium
 score; C
C
A
, com
m
on carotid artery; IC
A
, internal carotid artery; IM
T, intim
a-m
edia 
thickness; A
B
I, ankle-brachial index. †C
V
D
 is categorized in M
ESA
 as m
yocardial infarction/stroke/am
putation not due to injury. ††Expressed as parental history of coronary heart disease in G
EN
O
A
. *Sm
oking status categorized as 
never/ever in M
ESA
. **Sm
oking status categorized as never/form
er/current in G
EN
O
A
. §Physical activity categorized as m
oderate or heavy. §§A
frican A
m
ericans in G
EN
O
A
 had an available genetic risk score lim
ited to 55 of 62 
T2D
 SN
Ps. 
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Appendix Table 5 – Association between prevalent subclinical atherosclerosis measures and a T2D 
genotype risk score (GRS) comprised of 20 tag SNPs mostly linked with beta-cell function (GRSβ) 
in linear regression models of FHS and CARDIA cohorts. 
   
 FHS CARDIA 
 
 
 European Americans African Americans European Americans 
     
Basic Model Beta±SE P Beta±SE P Beta±SE P 
     
CACS -0.023±0.05 0.64 -0.011±0.03 0.71 0.005±0.02 0.76 
AACS -0.072±0.06 0.23 - - - - 
ICA-IMT -0.016±0.01 0.01 -0.001±0.00 0.55 0.001±0.00 0.31 
CCA-IMT -0.002±0.00 0.41 -0.001±0.00 0.60 0.000±0.00 0.69 
ABI -9.33E+08±0.00 0.94 - - - - 
     
Full Model       
     
CACS -0.021±0.05 0.69 -0.027±0.03 0.36 0.001±0.02 0.95 
AACS -0.012±0.06 0.85 - - - - 
ICA-IMT -0.018±0.01 0.007 -0.001±0.00 0.68 0.001±0.00 0.15 
CCA-IMT -0.004±0.00 0.15 -0.001±0.00 0.49 0.001±0.00 0.21 
ABI 0.001±0.00 0.46 - - - - 
     
 
AACS, abdominal aorta calcium score; CACS, coronary artery calcium score; CCA, common carotid artery; ICA, internal carotid artery; IMT, 
intima-media thickness; ABI, ankle-brachial index. Data expressed as mean±standard error. 
Appendix Table 6 – Association between prevalent subclinical atherosclerosis measures and a T2D 
genotype risk score (GRS) comprised of 10 tag SNPs mostly linked with insulin resistance (GRSIR) 
in linear regression models of FHS and CARDIA cohorts. 
   
 FHS CARDIA 
 
 
 European Americans African Americans European Americans 
     
Basic Model Beta±SE P Beta±SE P Beta±SE P 
     
CACS -0.004±0.07 0.95 -0.011±0.04 0.98 0.041±0.03 0.11 
AACS 0.112±0.08 0.17 - - - - 
ICA-IMT -0.003±0.01 0.77 0.000±0.00 0.93 -0.001±0.00 0.71 
CCA-IMT -0.004±0.00 0.29 0.001±0.00 0.46 -0.000±0.00 0.77 
ABI -7.74-06±0.00 0.99 - - - - 
     
Full Model       
     
CACS 0.036±0.08 0.65 0.005±0.04 0.89 0.025±0.03 0.32 
AACS 0.056±0.09 0.57 - - - - 
ICA-IMT -0.005±0.01 0.65 0.001±0.00 0.84 -0.000±0.00 0.83 
CCA-IMT -0.009±0.00 0.01 0.001±0.00 0.58 -0.001±0.00 0.63 
ABI 0.001±0.00 0.56 - - - - 
     
AACS, abdominal aorta calcium score; CACS, coronary artery calcium score; CCA, common carotid artery; ICA, internal carotid artery; IMT, 
intima-media thickness; ABI, ankle-brachial index. Data expressed as mean±standard error. 
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A
ppendix Figure 1 – D
istribution of the total sum
 of risk alleles com
prised in the T
2D
 G
R
S
62  in G
E
N
O
A
 (panel A
 and B
) and M
E
SA
 
cohorts (panels C
 to F), stratified by ethnicity. 
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A
ppendix Figure 2 – D
istribution of the total sum
 of risk alleles com
prised in the T
2D
 G
R
S
62 , G
R
S
β  and G
R
S
IR  in FH
S 
(panel A
, B
, C
, respectively) and in C
A
R
D
IA
 cohorts (panel D
 to I), stratified by ethnicity. 
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7.3 
 
 
 
Supplemental material Chapter 4 
 
Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with 
cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of 
the Verona Newly Diagnosed Type 2 Diabetes Study 
Experimental Design  
 
The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) is an ongoing 
study aiming at building a biobank of patients with newly diagnosed Type 2 
diabetes. As of Jan 1 2002, all patients referred to the Division of Endocrinology 
and Metabolic Diseases of University of Verona School of Medicine, whose 
diabetes has been diagnosed in the last six months, are asked to participate in this 
research. The clinical evidence on which the diagnosis of Type 2 diabetes has 
been made is reviewed and the diagnosis confirmed [1]. Patients are drug-naïve 
or, if already treated with antidiabetic drugs, undergo a treatment washout of at 
least one week before metabolic tests are performed. Among the exclusion criteria 
are age>75 years, non-Italian ancestry, insulin treatment, presence of anti-GAD 
antibodies, malignancies, and any condition severely impairing liver and/or 
kidney function. In this study, we report the data collected in 509 patients, whose 
characteristics are summarized in Table 1. 
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All subjects consumed a weight-maintaining diet containing 200-250 g of 
carbohydrate/day for at least three days before studies. Body weight was stable in 
all subjects for at least 1 month before studies. No subject participated in any 
heavy exercise. Each subject gave informed written consent before participating 
in the research, which was approved by the Human Investigation Committee of 
the Verona City Hospital. Measurements of standard clinical phenotypes were 
collected in all patients. Metabolic tests were carried out on two separate days in 
random order. On both days, patients were admitted to the Metabolic Clinic 
Research Center at 07:30 after an overnight fast. All studies were carried out in a 
quiet, temperature controlled (22° C) room. 
On one day an OGTT (75 g) was performed to assess beta cell function. For 
ethical reasons, the OGTT was not performed in patients presenting with FPG 
greater than 15 mmol/l. During the entire test patients were sitting in a 
comfortable cardiac chair. One teflon (21 g) venous catheter was inserted into an 
antecubital vein for blood sampling and kept patent with heparinized normal 
saline solution. After a 30’ rest to establish baseline and after collecting a 20 cc 
blood sample for leukocyte DNA extraction, at time = 0’ subjects ingested 75 g of 
glucose in 300 ml of water over 5 min. Blood samples to measure glucose, C-
peptide and insulin concentrations were collected at times -10’, 0’, +15’, +30’, 
+45’, +60’, +90’, +120’, +150’, +180’, +210’ and +240’. In some patients further 
blood samples were collected at +270’ and +300’. Urines were collected to 
measure glycosuria.  
On a separate day, a euglycemic insulin clamp was performed to assess insulin 
sensitivity [2]. During the entire test patients were lying in bed. One teflon 
catheter was introduced into an antecubital vein for the infusion of test 
substances. Another teflon catheter was placed retrogradely into a wrist vein for 
sampling arterialized venous blood, according to the “hot box” technique. After a 
30’ rest in bed to establish baseline, indirect calorimetry (at least 40’) was 
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performed as previously described, for a companion study [1]. At the end of 
calorimetric measures, baseline blood samples were collected and a standard 
euglycemic insulin (intravenous prime: 4.8 nmol.m-2 BSA; continuous infusion: 
240 pmol.min-1.m-2 BSA) clamp was performed [1]. Plasma glucose was allowed 
to decline until it reached 5.5 mmol/l, after which glucose clamping started with a 
glucose concentration goal of 5 mmol/l. The duration of the glucose clamp was at 
least of 120’, but it was prolonged, if and as needed, to ensure at least 60’ of 
insulin clamp at euglycemia in each patient. Timed blood samples were collected 
to measure hormone and substrate levels. In the last 45’ of the clamp indirect 
calorimetry was repeated to assess substrate oxidation and energy production rates 
for a companion study. Urines were collected to measure urea excretion rate. 
In both metabolic tests, all blood samples were collected in pre-chilled tubes and 
readily spun at 1,500 g. Plasma and serum specimens were stored at –80° C. 
 
Mathematical Modelling of Beta Cell Function 
 
The analysis of the glucose and C-peptide curves during the OGTT follows the 
general strategy described in previous publications [3, 4] with some modifications 
and builds upon previous works from other laboratories [5, 6]. The kinetics of C-
peptide is described with a two-compartment model, in which the two pools (1 
and 2) exchange with each other and the irreversible loss of the hormone is from 
pool 1, the same where C-peptide concentration is measured. C-peptide kinetic 
parameters are computed according to the equations by Van Cauter et al. [7]. 
Herein are the equations describing the model of glucose induced insulin 
secretion during an OGTT: 
dcp1(t)/dt = ISR(t) + cp2. k12 – (k01 + k21) . cp1   (Eq.1) 
 where ISR = insulin secretion rate, cp1 = C-peptide mass in the sampling 
(accessible) compartment, cp2 = C-peptide mass in the remote compartment, k12 
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and k21 = rate constants of the exchange between the two C-peptide 
compartments, and k01 = rate constant of the irreversible loss of C-peptide from 
the accessible compartment. Note that the values of the volume of distribution of 
C-peptide pool 1 (accessible compartment), k12, k21, and k01 are computed 
according to the equations by Van Cauter et al. [7]. 
 
ISR(t) = BSR + DSR(t) + PSR(t) (Eq.2) 
 
where BSR = basal insulin secretion rate, DSR = insulin secretion rate due to the 
derivative (or dynamic) component, and PSR = insulin secretion rate due the 
proportional (or static) component. 
 
BSR = CPss . V1 . k01 (Eq. 3) 
 
where CPss is basal C-peptide concentration and V1 is the volume of the 
accessible compartment of C-peptide. 
From the modeling viewpoint, DSR(t) and PSR(t) are the components which in 
intravenous glucose tolerance tests or hyperglycemic clamps describe classical 
first phase insulin secretion and second phase insulin secretion, respectively. 
Furthermore, from a physiological viewpoint, the sum of BSR and PSR(t) 
describes the relationship linking glucose concentration and insulin secretion rate, 
in the absence of the derivative component (DSR). 
 
DSR(t) and PSR(t) are mathematically defined as follows: 
DSR (t) = X1(t) . t-1  (Eq. 4) 
dX1(t) / dt = s1 . [dG(t)/dt]/[log(1.1+ t)] - X1(t) . t-1  if dG(t)/dt > 0 (Eq. 5) 
      dX1(t) / dt = - X1(t) . t-1        if dG(t)/dt ≤ 0 (Eq. 6)  
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, where s1 = glucose sensitivity of derivative control of insulin secretion, G = 
plasma glucose concentration, X1 = C-peptide (insulin) mass made available for 
the derivative component of insulin secretion, t = time constant of the derivative 
component of insulin secretion, and the term log(1.1 + t) accomodates the time-
associated decline of s1 documented in humans during a hyperglycemic stimulus 
[8].  
PSR(t) = X2(t) . d-1   (Eq. 7)  
dX2(t) / dt = s2 . [G(t) – q] - X2 (t) . d-1  (Eq. 8)  
 
where  s2 = glucose sensitivity of the proportional component of insulin secretion, 
X2 = C-peptide (insulin) mass made available for the proportional component of 
insulin secretion, d = time constant of the proportional component of insulin 
secretion, q = glucose threshold above which the beta-cell responds with the 
proportional component of insulin secretion to plasma glucose concentration.  
This model was implemented in the SAAM 1.2 software (SAAM Institute, 
Seattle, WA) [9] to estimate its unknown parameters. Numerical values of the 
unknown parameters were estimated by using nonlinear least squares. Weights 
were chosen optimally, i.e., equal to the inverse of the variance of the 
measurement errors, which were assumed to be additive, uncorrelated, with zero 
mean, and a coefficient of variation (CV) of 6-8%. The unknown parameters of 
the model are: CPss, s1, t, s2, d, and q. They were estimated with good precision, 
as shown by their CVs (Supplementary Table S1). 
A good fit of the model to data was obtained as shown by the table of the 
weighted residuals (Supplementary Table S2).  
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There are two main physiological outputs of the model: 
1. derivative control (units: [pmol.m-2 BSA] . [mmol.l-1.min-1] –1): it is the 
amount of insulin secreted in response to a rate of glucose increase of 1 
mmol/l per min which lasts for 1 minute;  
 
2. stimulus-response curve linking glucose concentration (x axis) to insulin 
secretion rate (y axis): as explained above, it is the sum of BSR and PSR. 
With the purpose of avoiding artefactual increases in the power of 
statistical analyses, we used the stimulus-response curve at the pre-
determined glucose concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mmol/l.  
 
 
 
Statistical analysis 
 
In this paper there are 5 outcome variables of interest (carotid atherosclerosis, 
ECG, insulin sensitivity, derivative control and proportional controls of beta cell 
function) and 10 SNPs of interest, giving rise to 50 comparisons and to the issue 
of correcting for false positive findings. We applied the two stage step-up linear 
procedure of Benjamini-Krieger-Yekutieli (BKY) [10] to control the false 
discovery rate (FDR) in our findings. The BKY procedure is a refinement of an 
earlier attempt [11] to improve the classical Benjamini-Hochberg method to 
control FDR [12]. It is based on the idea that in many sets of multiple 
comparisons the number of true null hypotheses is less than the number of 
hypotheses tested, and that this bit of information is relevant to compute FDR in 
multiple comparisons. 
Briefly, the BKY procedure tries to exploit the information content of the 
distribution of the p values of multiple comparisons. In Supplementary Figure 
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S2, the p values of the 50 comparisons performed in this study (y-axis) are plotted 
against their rank (x-axis), from the smallest to the largest. If all 50 null 
hypotheses tested were true, the p values should follow the straight line of 
Supplementary Figure S2. The observed p values at some point deviate from the 
expected distribution. The BKY procedure uses the data to estimate the number of 
true null hypotheses, which by definition in our case can be only ≤ 50. With an 
iterative process of linear regression analyses, in our case the number of true null 
hypotheses was found to be 41, not 50. With a FDR set at 0.20, which is the 
highest acceptable FDR according to Benjamini and Yekutieli [13], this led us to 
reject 5 null hypotheses, i.e. to accept 5 results as statistically significant at a FDR 
of 0.20.  
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Figure S1 - Genomic position and LD values of the ENPP1, IRS1 and TRIB3 
genotyped variants, as selected by GEVALT (GEnotype Visualization and 
ALgorithmic Tool) software in the VNDS study sample.  
 
The upper portion of each figure shows the gene and the genomic position of the 
genotyped polymorphisms. The lower portion of the figure shows the LD value, 
calculated as r2, among the SNPs. The dotted lines connect each SNP name and 
position with the corresponding cell in the LD matrix. Increasing level of LD is 
shown by darker grayscale. Each number enclosed in the grey diamonds below 
each locus should be divided by 100 to obtain the actual r2 value (i.e. 6 means r2 = 
6/100 = 0.06 etc …). 
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Figure S2 - P values of the 50 comparisons of the main outcome variables (y-
axis) vs. the rank of the same p values from the lowest to the highest (x-axis).  
 
The straight line indicates the expected distribution of the p values if all the null 
hypotheses were true, and, therefore, to be accepted, i.e. if no “true” associations 
between SNPs and cardiometabolic phenotypes existed. 
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 Table S1. Coefficients of variation of the beta cell model parameters. CPss= basal C-
peptide concentration; s1 = parameter regulating glucose sensitivity of derivative control 
of insulin secretion, t = time constant of derivative control of insulin secretion, s2 = 
glucose sensitivity of proportional control of insulin secretion, δ = time constant of 
proportional control of insulin secretion, θ: glycemic threshold of proportional control of 
insulin secretion. 
	
	
	
	
	
	
	
	
	
Model	Parameter	 Coefficients	of	Variation	(%)	
Median	 I.Q.	Range	
CPss	 10.8	 6.9-18.3	
s1	 40.7	 24.2-83.4	
τ  60.3	 58.2-61.2	
s2	 16.2	 11.9-22.4	
δ  33.0	 21.4-66.7	
θ  13.4	 8.5-22.0	
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Table S2. Weighted residuals of the model fit to the C-peptide data of the OGTT. 
Data are presented as means±SD. The weighted residuals are a quantitative point-by-
point assessment of the goodness-of-fit of the model to the data: a theoretically perfect fit 
should generate weighted residuals with mean 0 and SD of 1. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
 	
 C-Peptide	weighted	residuals	
 Time	 15’	 30’	 45’	 60’	 90’	 120’	 150’	 180’	 210’	 240’	
														Mean	 -
0.397	
+0.118	 +0.199	 +0.267	 +0.115	 -
0.026	
+0.142	 +0.015	 +0.026	 +0.107	
													SD	 1.03	 1.14	 1.197	 1.263	 1.302	 1.213	 1.319	 1.268	 1.277	 1.164	
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Table S3. Pairwise Linkage Disequilibrium among the 13 SNPs of IRS1, ENNP1 and TRIB3 
loci in 1000Genomes Pilot1, panel CEU.* 
	
		
SNP	 Proxy	 Distance	 RSquared	 DPrime	 Chr	 Coordinate_HG18	 Locus	
rs6076472	 rs12626158	 9540	 0.104	 0.68	 20	 318150	 TRIB3	
rs6076472	 rs7265169	 4137	 0.098	 0.757	 20	 312747	 TRIB3	
rs6076472	 rs6139007	 179	 0.082	 1	 20	 308789	 TRIB3	
rs6076472	 rs6115830	 16616	 0.069	 0.524	 20	 325226	 TRIB3	
rs6076472	 rs2295490	 8295	 0.005	 0.095	 20	 316905	 TRIB3	
rs6139007	 rs12626158	 9361	 0.134	 0.608	 20	 318150	 TRIB3	
rs6139007	 rs6115830	 16437	 0.098	 0.55	 20	 325226	 TRIB3	
rs6139007	 rs2295490	 8116	 0.042	 1	 20	 316905	 TRIB3	
rs6139007	 rs7265169	 3958	 0.014	 1	 20	 312747	 TRIB3	
rs7265169	 rs2295490	 4158	 0.027	 0.287	 20	 316905	 TRIB3	
rs7265169	 rs6115830	 12479	 0.014	 0.572	 20	 325226	 TRIB3	
rs7265169	 rs12626158	 5403	 0.011	 0.535	 20	 318150	 TRIB3	
rs2295490	 rs12626158	 1245	 0.055	 0.426	 20	 318150	 TRIB3	
rs2295490	 rs6115830	 8321	 0	 0.061	 20	 325226	 TRIB3	
rs12626158	 rs6115830	 7076	 0.292	 0.569	 20	 325226	 TRIB3	
rs6939185	 rs9493119	 72231	 0.033	 0.522	 6	 132253111	 ENPP1	
rs6939185	 rs858340	 20007	 0.02	 0.198	 6	 132200887	 ENPP1	
rs6939185	 rs1044498	 33181	 0.005	 0.149	 6	 132214061	 ENPP1	
rs6939185	 rs4897549	 80303	 0	 0.012	 6	 132261183	 ENPP1	
rs858340	 rs9493119	 52224	 0.051	 0.459	 6	 132253111	 ENPP1	
rs858340	 rs4897549	 60296	 0.051	 0.247	 6	 132261183	 ENPP1	
rs858340	 rs1044498	 13174	 0.003	 0.259	 6	 132214061	 ENPP1	
rs1044498	 rs9493119	 39050	 0.278	 0.726	 6	 132253111	 ENPP1	
rs1044498	 rs4897549	 47122	 0.119	 0.463	 6	 132261183	 ENPP1	
rs9493119	 rs4897549	 8072	 0.019	 0.254	 6	 132261183	 ENPP1	
rs4675095	 rs1801278	 n/a n/a n/a n/a n/a IRS1	
rs1801278	 rs4675095	 n/a n/a n/a n/a n/a IRS1	
*	As	provided	by	the	SNAP	software	v.	2.2	housed	at	http://www.broadinstitute.org,	Broad	Institute	(Boston,	MA,	USA).	
n/a,	not	available.	
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Supplementary	 Table	 S4.	 Clinical	 and	 metabolic	 features	 of	 the	
VNDS	study	population.	
Variable	 All	
N	(M/F)	 597	(415/182)	
Age	(years)	 59	[52-66]	
BMI	(Kg/m2)	 29.3	[26.5-32.8]	
Waist	circumference	(cm)	 100	[93-108]	
Smokers	(%)	 47.9	
Fasting	plasma	glucose	(mmol/l)	 7.0	[6.1-7.9]	
2hr	plasma	glucose	(mmol/l)		 13.0	[10.5-16.1]	
HbA1cDCCT	(%)	 6.7	[6.2-7.5]	
HbA1cIFCC	(mmol/mol)	 49.7	[44.3-58.5]	
Triglycerides	(mmol/l)		 1.4	[1.0-2.0]	
HDL-cholesterol	(mmol/l)		 1.1	[1.0-1.3]	
Total	cholesterol	(mmol/l)	 4.9	[4.3-5.6]	
SBP	(mmHg)	 138	[124-150]	
DBP	(mmHg)	 82	[80-90]	
Insulin	Sensitivity	(µmol/min/m2	BSA)	 607	[380-865]	
Insulinogenic	Index	(mU/mmol)	 4.1	[2.2-7.3]	
CIR120’	(mU⋅L/mmol2)	 0.5	[0.2-1.3]	
Data	 are	 presented	 as	median	 [I.Q.	 range];	 BMI,	 Body	Mass	 Index;	 SBP,	
Systolic	Blood	Pressure;	DBP,	Diastolic	Blood	Pressure;	HbA1cDCCT,	Diabetes	
Control	 and	 Complication	 Trial-Aligned	 Hemoglobin	 A1c;	 HbA1cIFCC,	
International	 Federation	 of	 Clinical	 Chemistry-Aligned	 Hemoglobin	 A1c;	
CIR120’,	Corrected	Insulin	Response120’	
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Supplementary	Table	 S5.	Association	of	 IRS1,	 ENPP1	and	 TRIB3	genotypes	
with	 insulin	 sensitivity	 as	 assessed	 by	 euglycemic	 hyperinsulinemic	 clamp	
and	Matsuda	Index.	
SNP	(locus)	 Effect	allele†	
Genotype	 P-value	
rs858340	(ENPP1)	 A	 AA	 AG	 GG	 	
	 Matsuda	Index	 	 3.1±0.3	 3.4±0.1	 3.3±0.1	 0.82	
	 M	clamp*	 	 820±69.1	 664±23.3	 623±19.9	 0.008	
rs6939185	(ENPP1)	 A	 AA	 AG	 GG	 	
	 Matsuda	Index	 	 3.7±0.3	 3.3±0.1	 3.2±0.1	 0.01	
	 M	clamp	 	 727±44.1	 653±20.8	 638±25.6	 0.05	
rs9493119	(ENPP1)	 G	 GG	 AG	 AA	 	
	 Matsuda	Index	 	 2.7±0.6	 3.9±0.4	 3.3±0.1	 0.21	
	 M	clamp	 	 623±19.9	 664±23.3	 820±69.1	 0.24	
rs4897549	(ENPP1)	 A	 AA	 AG	 GG	 	
	 Matsuda	Index	 	 3.2±0.3	 3.4±0.2	 3.4±0.1	 0.45	
	 M	clamp	 	 662±60.7	 679±24.8	 634±20.1	 0.45	
rs6115830	(TRIB3)	 A	 AA	 AG	 GG	 	
	 Matsuda	Index	 	 3.3±0.2	 3.4±0.1	 3.2±0.2	 0.64	
	 M	clamp	 	 667±27.9	 655±22.3	 639±30.8	 0.23	
rs6139007	(TRIB3)	 G	 GG	 AG	 AA	 	
	 Matsuda	Index	 	 2.8±0.3	 3.5±0.2	 3.3±0.1	 0.68	
	 M	clamp	 	 668±53.3	 677±23.9	 638±21.0	 0.14	
rs6076472	(TRIB3)	 C	 CC	 AC	 AA	 	
	 Matsuda	Index	 	 3.4±0.3	 3.3±0.1	 3.3±0.1	 0.76	
	 M	clamp	 	 667±53.2	 651±23.7	 663±21.3	 0.10	
rs7265169	(TRIB3)	 A	 AA	 AC	 CC	 	
	 Matsuda	Index	 	 3.07±0.62	 3.21±0.24	 3.36±0.09	 0.74	
	 M	clamp	 	 384±112.1	 594±32.7	 668.8±17.0	 0.24	
rs1801278	(IRS1)	 A	 AA	 AG	 GG	 	
	 Matsuda	Index	 	 3.9±2.6	 3.4±0.2	 3.3±0.1	 0.85	
	 M	clamp	 	 829±356.3	 655±40.7	 653±16.1	 0.74	
rs4675095	(IRS1)	 A	 AA	 AT	 TT	 	
	 Matsuda	Index	 	 2.3±0.3	 3.7±0.3	 3.3±0.1	 0.23	
	 M	clamp	 	 672±43.0	 674±39.7	 651±16.2	 0.59	
	
Generalized	Linear	Model,	additive	genetic	model	 (outcome	trait:	 insulin	sensitivity,	
expressed	 as	 Matsuda	 Index	 or	 M-clamp;	 covariates:	 age,	 sex,	 BMI).	 †	 The	 minor	
allele,	 defined	 according	 to	 the	 MAF	 in	 our	 population,	 was	 considered	 as	 effect	
allele.	*	M	clamp	unit:	µmol/min/m2	Body	Surface	Area.	Matsuda	Index	and	M-clamp	
were	expressed	as	mean±SE.	
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Supplementary	Table	S6.	MAGIC	lookup:	Ln(HOMA-IR)	
SNP	 Effect	allele†	
Other	
allele	 MAF	 Effect	 SE	 P-value	
rs4675095	(IRS1)	 A	 T	 0.067	 -3.40E-02	 8.80E-03	 0.0001171	
rs1801278	(IRS1)	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
rs858340	(ENPP1)	 T	 C	 0.246	 -9.50E-03	 4.40E-03	 0.03142	
rs6939185	(ENPP1)	 A	 G	 0.396	 -3.40E-03	 4.10E-03	 0.4157	
rs9493119	(ENPP1)	 A	 G	 0.062	 9.00E-04	 1.10E-02	 0.9295	
rs4897549	(ENPP1)	 T	 C	 0.178	 -3.60E-03	 4.50E-03	 0.4319	
rs6139007	(TRIB3)	 T	 C	 0.195	 1.30E-02	 6.10E-03	 0.02906	
rs7265169	(TRIB3)	 A	 C	 0.106	 -9.50E-03	 1.40E-02	 0.4873	
rs6115830	(TRIB3)	 T	 C	 0.379	 1.50E-03	 4.30E-03	 0.72	
rs6076472	(TRIB3)	 T	 G	 0.274	 -1.60E-03	 6.90E-03	 0.8129	
†According	to	the	MAGIC	database.	n/a,	not	available;	Ln,	natural	logarithm.	HOMA-IR,	IR-Homeostatic	Model	
Assessment;	MAF,	Minor	Allele	Frequency;	SE,	Standard	Error.	
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Supplementary	Table	S7.	MAGIC	lookup:	Ln(HOMA-B)	
SNP	 Effect	allele†	
Other	
allele	 MAF	 Effect	 SE	 P-value	
rs4675095	(IRS1)	 A	 T	 0.067	 -2.10E-02	 7.50E-03	 0.004202	
rs1801278	(IRS1)	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
rs858340	(ENPP1)	 T	 C	 0.246	 -4.20E-03	 3.60E-03	 0.2396	
rs6939185	(ENPP1)	 A	 G	 0.396	 -1.90E-03	 3.40E-03	 0.569	
rs9493119	(ENPP1)	 A	 G	 0.062	 -4.90E-03	 9.40E-03	 0.6041	
rs4897549	(ENPP1)	 T	 C	 0.178	 2.20E-03	 3.70E-03	 0.5512	
rs6139007	(TRIB3)	 T	 C	 0.195	 9.00E-03	 5.00E-03	 0.07133	
rs7265169	(TRIB3)	 A	 C	 0.106	 -9.50E-03	 1.40E-02	 0.4873	
rs6115830	(TRIB3)	 T	 C	 0.379	 8.00E-04	 3.60E-03	 0.8275	
rs6076472	(TRIB3)	 T	 G	 0.274	 4.00E-04	 6.40E-03	 0.9553	
†According	 to	 the	MAGIC	 database.	 n/a,	 not	 available;	 Ln,	 natural	 logarithm.	 HOMA-B,	 Beta-cell	 function	 -	
Homeostatic	Model	Assessment;	MAF,	Minor	Allele	Frequency;	SE,	Standard	Error.	
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Supplementary	Table	S8.	MAGIC	lookup:	Insulin	Sensitivity	Index	(ISI)*	
SNP	 Effect	allele†	
Other	
allele	 MAF	 Effect	 SE	 P-value	
rs4675095	(IRS1)	 A	 T	 0.067	 9.70E-02	 5.50E-02	 0.076463	
rs1801278	(IRS1)	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
rs858340	(ENPP1)	 C	 T	 0.246	 7.00E-03	 2.70E-02	 0.792024	
rs6939185	(ENPP1)	 G	 A	 0.396	 -2.40E-02	 2.40E-02	 0.327156	
rs9493119	(ENPP1)	 A	 G	 0.062	 -8.90E-03	 6.70E-02	 0.894582	
rs4897549	(ENPP1)	 C	 T	 0.178	 -1.80E-02	 2.40E-02	 0.451828	
rs6139007	(TRIB3)	 T	 C	 0.195	 -9.90E-04	 3.80E-02	 0.979483	
rs7265169	(TRIB3)	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
rs6115830	(TRIB3)	 C	 T	 0.379	 -1.70E-02	 2.50E-02	 0.500486	
rs6076472	(TRIB3)	 T	 G	 0.274	 2.00E-02	 2.90E-02	 0.503135	
†According	 to	 the	MAGIC	database.	 n/a,	 not	 available;	 Ln,	 natural	 logarithm.	MAF,	Minor	Allele	 Frequency;	 SE,	
Standard	 Error.	 *	 Calculated	 as	 Matsuda	 Index,	 as	 follows:	 10,000/[(Glucose0’⋅Insulin0’)⋅(Mean	 OGTT	 glucose	
concentration)⋅(mean	OGTT	insulin	concentration)]1/2	
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Supplementary	Table	S9.	MAGIC	lookup:	CIR30’	
	
SNP	 Effect	allele†	
Other	
allele	 MAF	 Effect	 SE	 P-value	
rs4675095	(IRS1)	 A	 T	 0.067	 -3.70E-03	 5.00E-02	 0.940667	
rs1801278	(IRS1)	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
rs858340	(ENPP1)	 C	 T	 0.246	 4.10E-02	 2.30E-02	 0.079624	
rs6939185	(ENPP1)	 G	 A	 0.396	 3.50E-02	 2.10E-02	 0.095807	
rs9493119	(ENPP1)	 A	 G	 0.062	 -1.60E-01	 5.50E-02	 0.002835	
rs4897549	(ENPP1)	 C	 T	 0.178	 1.80E-03	 2.20E-02	 0.935155	
rs6139007	(TRIB3)	 T	 C	 0.195	 -3.00E-02	 3.20E-02	 0.351976	
rs7265169	(TRIB3)	 C	 A	 0.106	 -6.90E-04	 3.50E-02	 0.984125	
rs6115830	(TRIB3)	 C	 T	 0.379	 -1.80E-02	 2.10E-02	 0.399347	
rs6076472	(TRIB3)	 T	 G	 0.274	 -3.50E-02	 2.60E-02	 0.172351	
†According	to	the	MAGIC	database.	n/a,	not	available;	Ln,	natural	 logarithm.	CIR30’,	Corrected	Insulin	Response	at	
30’	after	a	75g-OGTT;	MAF,	Minor	Allele	Frequency;	SE,	Standard	Error.	
 
	
	
	
	
	
	
	
	
		
 
 
